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ABSTRACT
Background: Small-quantity (SQ) lipid-based nutrient supplements
(LNSs) provide many nutrients needed for brain development.
Objectives: We aimed to generate pooled estimates of the effect of
SQ-LNSs on developmental outcomes (language, social-emotional,
motor, and executive function), and to identify study-level and
individual-level modifiers of these effects.
Methods: We conducted a 2-stage meta-analysis of individual participant data from 14 intervention against control group comparisons
in 13 randomized trials of SQ-LNSs provided to children age
6–24 mo (total n = 30,024).
Results: In 11–13 intervention against control group comparisons
(n = 23,588–24,561), SQ-LNSs increased mean language (mean
difference: 0.07 SD; 95% CI: 0.04, 0.10 SD), social-emotional (0.08;
0.05, 0.11 SD), and motor scores (0.08; 95% CI: 0.05, 0.11 SD)
and reduced the prevalence of children in the lowest decile of these

scores by 16% (prevalence ratio: 0.84; 95% CI: 0.76, 0.92), 19%
(0.81; 95% CI: 0.74, 0.89), and 16% (0.84; 95% CI: 0.76, 0.92),
respectively. SQ-LNSs also increased the prevalence of children
walking without support at 12 mo by 9% (1.09; 95% CI: 1.05,
1.14). Effects of SQ-LNSs on language, social-emotional, and motor
outcomes were larger among study populations with a higher stunting
burden (≥35%) (mean difference: 0.11–0.13 SD; 8–9 comparisons).
At the individual level, greater effects of SQ-LNSs were found on
language among children who were acutely malnourished (mean
difference: 0.31) at baseline; on language (0.12), motor (0.11), and
executive function (0.06) among children in households with lower
socioeconomic status; and on motor development among later-born
children (0.11), children of older mothers (0.10), and children of
mothers with lower education (0.11).
Conclusions: Child SQ-LNSs can be expected to result in modest
developmental gains, which would be analogous to 1–1.5 IQ points
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on an IQ test, particularly in populations with a high child stunting
burden. Certain groups of children who experience higher-risk
environments have greater potential to benefit from SQ-LNSs in
developmental outcomes. This trial was registered at www.crd.
york.ac.uk/PROSPERO as CRD42020159971.
Am J Clin Nutr
2021;114:43S–67S.
Keywords: language development, motor development, socialemotional development, executive function, child undernutrition,
complementary feeding, nutrient supplements

Introduction
Brain development occurs rapidly in utero and during the
first few years after birth, laying the foundation of the neural
structures that underlie children’s development of cognitive
skills, such as language and executive function, as well as socialemotional and motor skills (1). Adequate availability of nutrients,
such as iron, iodine, zinc, B-vitamins, and essential fatty acids,
is necessary for the neurodevelopmental processes that occur
during this period, such as myelination, synaptogenesis, and axon
and dendrite growth (2). Inadequate dietary intake during this
foundational period could lead to lasting structural and functional
neurodevelopmental deficits (3). At age 6–24 mo, children are
at particular risk of inadequate dietary intake of these nutrients
as they transition from exclusive breastfeeding to joining family
meals, in what is called the complementary feeding period (4).
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Small-quantity (SQ) lipid-based nutrient supplements (LNSs)
were designed to fill this gap between the needs and dietary
intakes of key nutrients experienced by many children during this
time period, for prevention of undernutrition in low- and middleincome countries (LMICs). SQ-LNSs are typically made from
vegetable oil, peanut paste, milk powder, and sugar, with added
vitamins and minerals, thus providing many of the micronutrients
and fatty acids that are necessary for brain development (5).
SQ-LNSs provide ∼120 kcal/d, whereas other LNS products
(medium- and large-quantity) provide more energy and are
designed for treatment of moderate and severe acute malnutrition.
Two previous systematic reviews and meta-analyses have
addressed the effects of LNSs provided during the complementary feeding period on developmental outcomes (6, 7).
In a 2019 Cochrane review by Das et al. (6), the authors
provided a narrative review of effects on these outcomes, but
were not able to generate pooled estimates owing to differences
between studies in measurement and reporting of developmental
outcomes. The other meta-analysis by Tam et al. (7) generated
pooled estimates of the effects of LNSs using published data
from studies on various developmental outcomes, including a
total of <3600 children. SQ-LNSs had significant positive effects
on mean language scores (effect size: 0.13 SD; 5 studies), socialemotional scores (0.12 SD; 5 studies), and motor scores (0.13 SD;
6 studies), and no effect on executive function (3 studies) or on
the prevalence of children standing or walking without support at
age 12 mo (4 studies), although heterogeneity across trials was
moderate to substantial.
Here, we report an individual participant data (IPD) metaanalysis (8) of SQ-LNSs provided during the complementary
feeding period, which adds to the current evidence-base in several
ways. First, we included a larger number of trials (13 trials)
and children (30,024) than previous meta-analyses. Second, we
analyzed IPD, rather than aggregate data from published reports,
which enabled harmonization of the calculation of developmental
outcomes across trials. Third, we examined study-level and
individual-level factors that may modify the effect of SQLNSs on developmental outcomes. Identifying characteristics of
children and populations who experience greater benefits from
SQ-LNSs, or are more likely to respond to the intervention, may
be useful to inform public health programs and policies. Our
first objective was to generate pooled estimates of the effect of
randomized controlled trials of SQ-LNSs provided to infants and
young children in the age range of 6–24 mo, compared with children who received no intervention or an intervention without any
nutritional supplement, on developmental outcomes. The other
2 objectives were to identify study-level modifiers (Objective 2)
and individual-level modifiers (Objective 3) of these effects.

Methods
The protocol for this IPD meta-analysis was registered as
PROSPERO CRD42020159971 (9). The detailed protocol was
posted to Open Science Framework before analysis (10) and
updated after consultations with co-investigators before finalizing
the analysis plan. The results are reported according to Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA)-IPD guidelines (11). The analyses were approved by
the institutional review board of the University of California,
Davis. All individual trial protocols were approved by appropriate
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institutional ethics committees. The methods are presented in
detail in a companion article published in the same journal issue
(12) and summarized here.
Inclusion and exclusion criteria for this IPD meta-analysis
We included prospective randomized controlled trials of SQLNSs provided to children in the age range of 6–24 mo that met
the inclusion criteria listed in Dewey et al. (12). In addition to
those criteria, for the analyses presented here, we only included
trials that measured ≥1 developmental outcome of interest, as
described below.
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(attrition bias), selective reporting (reporting bias), and other
sources of bias (13) (Supplemental Figure 1). Any discrepancies
were resolved by discussion or consultation with the core
working group, as needed. To assess risk of bias across studies,
for each outcome that was measured in a subset of studies,
we compared study-level maternal education (percentage who
completed primary) and child 18-mo stunting burden to check
for substantial differences between the trials included and trials
excluded. The same reviewers also assessed the quality of
evidence for each outcome across all studies based on the 5
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) criteria: risk of bias, inconsistency of
effect, imprecision, indirectness, and publication bias (14).

Search methods and identification of studies
We identified studies cited in a recent systematic review and
meta-analysis of child LNSs (6) and through database searches,
as described in Dewey et al. (12).
Data collection
We invited all principal investigators of eligible studies to
participate in this IPD meta-analysis. We provided a data
dictionary listing definitions of variables requested for pooled
analysis. For further details, see Dewey et al. (12). The variables
requested for this IPD meta-analysis were 1) intervention
group, as determined by each trial design; 2) randomization
cluster, if cluster-randomized; 3) child sex; 4) child age at
developmental assessment; 5) whether each motor milestone
had been attained by the child at the time of assessment; 6)
continuous unstandardized developmental outcome scores of
interest measured at baseline (before child supplementation)
and postsupplementation, as available, calculated according to
the established method for the tool used in each study; and 7)
indicator variables for potential effect modifiers, as prespecified
in the analysis plan. Study-level effect modifiers included
variables reflecting sample characteristics and study design
(Box 1). Individual-level effect modifiers included maternal,
child, and household characteristics (Box 1).
IPD integrity
We checked data for completeness by ensuring that the study
sample sizes in our pooled data set were the same as in study
protocols and publications. We also checked summary statistics,
such as means and SDs, in our data set against published
values for each trial to ensure consistency. Implausible values
were inspected for errors and truncated to 5 or −5 SD from
the mean z score (≤0.2% of values for each outcome, with
the highest percentage for motor, gross, and fine motor scores:
0.18–0.20%).
Assessment of risk of bias and quality of evidence in each
study and across studies
Independent reviewers (KRW, CDA, ELP) assessed risk of
bias in each trial against the following criteria: random sequence
generation and allocation concealment (selection bias), blinding
of participants and personnel (performance bias), blinding of
outcome assessment (detection bias), incomplete outcome data

Specification of outcomes and effect measures
The following primary and secondary outcomes were prespecified in the analysis plan. Primary outcomes were language,
motor, and social-emotional z scores reported on a continuous
scale; whether the child was in the lowest decile of continuous
language z scores, motor z scores, and social-emotional z scores;
and walking without support at 12 mo. Secondary outcomes were
continuous gross and fine motor z scores if these were reported
separately, continuous executive function z scores and whether
the child was in the lowest decile of executive function z scores,
plus whether the child had achieved 4 motor milestones at 12 mo
(crawling, standing with support, standing without support, and
walking with support) and 5 motor milestones at 18 mo (the same
4 plus walking without support).
z Scores were standardized within each study by regressing
the unstandardized developmental score on child age and sex
and calculating the standardized residuals. This approach is
analogous to calculating length-for-age z score (LAZ) in that
the score represents deviations from the mean score for a given
child’s age and sex in units of SD. However, developmental
outcome z scores were calculated in reference to each withinstudy distribution, rather than an external standard. For example,
a female child with a language z score of −1 scored 1 SD below
the mean of other female children of the same age in her study
sample.
The lowest decile of each z score was also defined for each
study based on the within-study distribution. Given that most
of the developmental assessment tools used in these studies do
not have validated cutoffs to identify children at risk of delayed
neurodevelopment, we used the lowest decile of scores as a proxy
for children who may be at the greatest risk of experiencing
developmental delay. We thus considered the lowest decile of
scores to be an adverse developmental outcome. We selected the
lowest decile as the cutoff because it is sufficiently low to capture
poor development in populations that as a whole may lag behind
populations with no environmental constraints on achieving
developmental potential, and high enough to allow adequate
power to detect group differences. In addition, some standard
developmental assessments have used the lowest decile to
define delay, for example, the MacArthur-Bates Communicative
Development Inventory (CDI), which was adapted to assess
language in 6 of the studies included in this IPD meta-analysis
(15).
If any study used multiple tools or scores to assess the same
domain at endline (e.g., language), we selected the tool or score
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Box 1.
Potential effect modifiers1

Study-level effect modifiers2
• Geographic region (WHO region: Sub-Saharan Africa vs.
Southeast Asia Region)
• Stunting burden among control group children at 18 mo of age
(≥35% vs. <35%)3
• Malaria prevalence (country-specific, closest in time to the
study: ≥10% vs. <10%)4
• Anemia prevalence (country-specific, closest in time to the
study: ≥60% vs. <60%)5
• Source water quality (study-specific, <75% vs. ≥75%
prevalence of improved drinking water)6
• Sanitation (study-specific, <50% vs. ≥50% prevalence of
improved sanitation)7
• Duration of child supplementation (study target: >12 mo vs.
≤12 mo)
• Child age at baseline or endline
• Frequency of contact for intervention delivery or outcome
assessments during the study (weekly vs. monthly)
• Compliance (mean percentage compliance in SQ-LNS group:
≥80% vs. <80%)8

Individual-level effect modifiers
• Maternal height (<150.1 cm vs. ≥150.1 cm)9
• Maternal BMI (<20 kg/m2 vs. ≥20 kg/m2 )
• Maternal age (<25 y vs. ≥25 y)
• Maternal education (no formal or incomplete primary vs. complete primary or
greater)
• Maternal depressive symptoms (< study 75th percentile vs. ≥ study 75th
percentile)10
• Child sex (female vs. male)
• Child birth order (firstborn vs. later-born)
• Child baseline stunted (length-for-age z score < −2 SD vs. ≥ −2)
• Child baseline acute malnutrition (weight-for-length z score < −2 SD or
midupper arm circumference < 125 mm)
• Child baseline anemia (Hb < 110 g/L vs. ≥110 g/L)
• Household socioeconomic status (< study median vs. ≥ study median)11
• Household food security (moderate to severe food insecurity vs. secure to mild
food insecurity)12
• Household source water quality (unimproved vs. improved)6
• Household sanitation (unimproved vs. improved)7
• Home environment (< study median vs. ≥ study median)13
• Season at the time of developmental outcome assessment (rainy vs. dry)14

1 Comparisons

follow the format nonreference vs. reference category. Hb, hemoglobin; SQ-LNS, small-quantity lipid-based nutrient supplement.
identified potential study-level effect modifiers before receipt of data, and categorized individual studies based on the distribution of effect
modifier values across all studies before conducting hypothesis-testing.
3 Based on 18-mo data because baseline data were not available for all trials; cutoff chosen at approximately the median across trials.
4 World Malaria Report 2018 (74); cutoff chosen based on the median across trials.
5 Country-specific prevalence of anemia among children age 6–59 mo, based on national surveys (see Supplemental Table 3).
6 Improved water source includes piped water, boreholes or tubewells, protected dug wells or springs, rainwater, and packaged or delivered water
(see Supplemental Table 3) (75); based on baseline data, excluding arms that received water, sanitation, and hygiene interventions; cutoff chosen at
approximately the median across trials.
7 Improved sanitation includes flush/pour flush to piped sewer system, septic tanks, or pit latrines; ventilated improved pit latrines, composting toilets,
or pit latrines with slabs (see Supplemental Table 3) (76); cutoff chosen at approximately the median across trials.
8 Study-specific, as reported based on a study-defined indicator (see Supplemental Table 3).
9 Cutoff based on −2 SD for height at 19 y of age at https://www.who.int/growthref/hfa_girls_5_19years_z.pdf?ua=1.
10 Study-specific (see Supplemental Table 3); cutoff chosen to reflect the top quartile for risk of depression.
11 Based on a study-defined, study-specific assets index.
12 Study-specific (see Supplemental Table 3).
13 As measured by the Family Care Indicators, Home Observation for the Measurement of the Environment Inventory, or other similar tools (see
Supplemental Table 3).
14 Rainy compared with dry, based on study- and child-specific average rainfall during the month of measurement and 2 mo prior (see Supplemental
Table 3).
2 We

that was used in the greatest number of other studies included
in this IPD meta-analysis. For social-emotional scores, if any
study reported a social-emotional difficulties score for which
a higher score indicated greater problems, we reversed those
scores so that for all scores, a higher score represented greater
social-emotional competence. For the milestone assessment,
we only used reports or observations of the child’s ability
on the day of assessment, not retrospective reports of age of
milestone achievement, because the latter is subject to potential
recall inaccuracy. We used milestone data collected within 1
mo of the target age (12 or 18 mo). If both observation and

parent-report data existed at the same time point, we used
observation data.
The principal measure of effect for continuous outcomes was
the mean difference between intervention and comparison groups
at endline, defined as the principal postintervention time point
as reported for trials with infrequent child assessment or at the
age closest to the end of the supplementation period for trials
with monthly child assessment. The principal measure of effect
for binary outcomes was the prevalence ratio at endline or at
the targeted age of milestone assessment (12 or 18 mo). We
also estimated prevalence differences as secondary assessments
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of binary outcomes. Prevalence ratios quantify the relative
difference in proportions between groups, whereas prevalence
differences are the difference in absolute percentage points.
Prevalence differences are less consistent than prevalence ratios
(13); however, they are important for estimating the public health
impact of an intervention.
The treatment and comparisons of interest were provision
of children with SQ-LNSs (< ∼125 kcal/d, with or without
co-interventions), compared with children who received no
intervention or an intervention without any type of LNS or
other child nutritional supplement (herein labeled “control”).
Examples of other types of interventions that have been delivered
with or without LNSs are water, sanitation, and hygiene (WASH)
interventions or child morbidity monitoring and treatment.
In several trials, child LNS has been delivered to children
whose mothers received maternal LNS during pregnancy and
postpartum. Given that maternal supplementation may have an
additive effect, we originally planned to include trial arms that
provided both maternal and child LNSs in a sensitivity analysis
only (i.e., the all-trials analysis). However, to maximize study
inclusion and participant sample size, and to allow for sufficient
numbers of trials to examine effect modification for certain
outcomes, we decided after initial registration of the protocol
but before completing statistical analyses that the results of the
all-trials analysis would be presented as the principal findings if
the following criteria were met, as determined for each outcome:
if the main effects did not differ between the child-LNS-only
analysis (excluding maternal plus child LNS arms) and the alltrials analysis (including maternal plus child LNS arms) by
>20% for continuous outcomes or by >0.05 for prevalence
ratios. Two additional sensitivity analyses were also conducted,
as described below.

Synthesis methods and exploration of variation in effects
We conducted 3 types of analyses, corresponding to the
3 objectives, to investigate 1) full-sample main effects of the intervention, 2) effect modification by study-level characteristics, and
3) effect modification by individual-level characteristics. We used
a 2-stage approach for all analyses. This approach is preferred
when incorporating cluster-randomized trials because it allows
intracluster correlations to be study-specific (8). All analyses
followed a complete-case intention-to-treat framework (16).
In the first stage, we estimated intervention compared with
control group effects (mean differences or prevalence ratios)
within each individual study. Given that continuous outcomes
represented deviations from the study sample mean score for
a given child’s age and sex in units of SD, these first-stage
individual study estimates represent mean differences between
SQ-LNS and control groups in units of SD. For longitudinal study
designs that provided baseline developmental assessment data,
we adjusted for baseline score when estimating the intervention
effect. For cluster-randomized trials, we used robust SEs to
account for participant dependence within clusters.
In the second stage, first-stage estimates were pooled using
inverse-variance weighted fixed effects. A fixed-effect approach
generates estimates viewed as a typical intervention effect
from the studies included in the analysis. This was prespecified in our statistical analysis plan because we anticipated
similar intervention effects and similar individual-level effect
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modification patterns across studies. As a robustness check
of this assumption, we also conducted a sensitivity analysis
calculating pooled estimates using inverse-variance weighted
random effects (17, 18). If there were <3 comparisons to include
in a pooled estimate then the pooled estimate was not generated
(e.g., if <3 comparisons were represented within a study-level
effect modification category). This was the case for most of
the milestones, therefore we did not examine study-level or
individual-level effect modification for any of the 9 individual
milestones specified as secondary outcomes.
For Objective 1, we pooled the first-stage estimates to generate
a pooled point estimate, 95% CI, and corresponding P value.
For Objective 2, we used a bivariate random-effects metaregression to test the association of study-level characteristics
with study intervention effect estimates. For Objective 3, we first
estimated the parameter corresponding to the interaction term of
the effect modifier and the intervention for each study (19). We
then generated pooled intervention effect estimates within each
category of the effect modifier to determine how the intervention
effect in one subgroup differed from the intervention effect in the
specified reference subgroup. For further details, see Dewey et al.
(12).
Heterogeneity of effect estimates was assessed using I2 and
Tau2 statistics, within strata when relevant (20). We used a P value
of <0.05 for main effects and a P-for-interaction < 0.10 for effect
modification. Given that developmental outcomes are interrelated
and the effect modification analyses are inherently exploratory,
we did not adjust for multiple hypothesis testing because doing so
may be unnecessary and counterproductive owing to increasing
the likelihood of type 2 error (21).
Sensitivity analyses
Two sensitivity analyses were conducted in addition to those
aforementioned (the child-LNS only analysis, all-trials analysis,
and fixed- and random-effects models). First, we excluded
passive control arms, defined as groups of participants who
received no intervention and had no contact with project staff
between enrollment and endline. Second, we separated comparisons within trials that included multicomponent interventions to
attempt to isolate the effect of SQ-LNSs. For example, if a trial
provided a water intervention to one group, a water plus sanitation
intervention to a second group, and a water and sanitation plus
SQ-LNS intervention to a third group, this sensitivity analysis
would only compare the water and sanitation plus SQ-LNS
arm with the water and sanitation arm. The all-trials analysis
and child-LNS-only analysis would include both groups that
did not receive SQ-LNSs in the comparison group, whereas
the sensitivity analysis would exclude the group that received
the water intervention only. Behavior change communication
and other messaging promoting recommended infant and young
child feeding (IYCF) practices were not considered additional
components. Supplemental Table 1 lists all trial arms and
specifies which comparisons were made in each sensitivity
analysis.
In addition, we conducted post hoc analyses to examine effects
within subgroups of trials based on 2 aspects of the intervention
design: 1) whether the trial was or was not conducted within an
existing program, and 2) the extent of the social and behavior
change communication on IYCF that was provided (minimal
compared with expanded).

48S

Supplement
2107 records idenﬁed through
database searching

Das et al. (6)

1407 records aer duplicates
removed

1359 excluded on the basis
of tle and abstract

17 trials (54 reports)
included in the Cochrane
review

1466 records screened

5 ongoing trials

17 duplicate records
already included in Das
et al. (6)

14 trials (24 reports)
excluded: non-RCT, nonSQ-LNS, malnutrion, no
appropriate comparison
90 full-text reports assessed for
eligibility

5 ongoing trials (5 reports)
excluded: no data
Systemac reviews (3
reports) excluded

6 trials (8 reports) with
addional recently
published data

15 trials (58 reports) for which IPD
were sought

1 trial (1 report) excluded
from IPD analysis: no IPD
available

14 trials (65 reports) for which IPD
were provided

1 trial (1 report) excluded:
no development outcomes
collected

13 trials included
in all-trials analysis

11 trials included
in child-LNS-only
analysis

FIGURE 1 Study inclusion flow diagram. IPD, individual participant data; LNS, lipid-based nutrient supplement; RCT, randomized controlled trial; SQ,
small-quantity.

Results
Literature search and trial characteristics
Of the 1466 publications identified through the search strategy
and review of other meta-analyses and systematic reviews,
90 titles and abstracts were identified as relevant. Based on
review of the full texts, 14 trials met the inclusion criteria
and IPD were requested (22–36). Investigators for 1 trial were
unable to participate (36). In that trial, only fine and gross
motor outcomes were reported, therefore we examined pooled
main effects on these 2 outcomes both without and with this

trial, by calculating Hedges’ g (37) based on endline values
extracted from the published report. For all other analyses, 13
trials were included in the IPD meta-analysis for developmental
outcomes (22, 26, 30, 33, 38–47) (Figure 1). One trial reported
child development as a primary outcome (29), and the other
12 reported child development as secondary outcomes. One
trial, SHINE in Zimbabwe (35, 46), contributed 2 comparisons
because it was designed a priori to report results separately for
HIV-exposed and HIV-unexposed children. Thus, 14 SQ-LNS
against control group comparisons from 13 trials were analyzed.
Of the 14 comparisons, language outcomes were reported for
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2 Developmental

1 LNS,

lipid-based nutrient supplement; SQ, small-quantity.
assessments were conducted only in the cross-sectional sample, not the longitudinal sample, therefore the longitudinal sample was not included in the participant count.

4558
2565
4572
1176
194
1103
322
6756
3217
674
999
1927
1961
4568
2567
4824
2647
194
1113
322
6815
3438
675
999
19272
4347
N
Y/N
N
N
N
Y
N
N
Y/N
Y
N
N
N
12
18
18
9
6
12
3–6
18
6–12
12
12
18
12
6
6
6
9
6
6
6–11
6
6–11
6
6
6
6

Duration, mo
Age at start, mo
Trial name

JiVitA-4
RDNS
WASH B-B
iLiNS-Zinc
GHANA
iLiNS-DYAD-G
HAITI
WASH B-K
MAHAY
iLiNS-DYAD-M
iLiNS-Dose
PROMIS
SHINE
Christian et al. (22)
Dewey et al. (23), Matias et al. (38)
Luby et al. (24), Tofail et al. (39)
Hess et al. (25), Prado et al. (40)
Adu-Afarwuah et al. (26)
Adu-Afarwuah et al. (27, 41)
Iannotti et al. (28, 42)
Null et al. (29), Stewart et al. (43)
Galasso et al. (30)
Ashorn et al. (31), Prado et al. 44)
Maleta et al. (32), Prado et al. (45)
Huybregts et al. (33)
Humphrey et al. (34), Gladstone et al. (46)
Prendergast et al. (35), Chandna et al. (47)
Bangladesh
Bangladesh
Bangladesh
Burkina Faso
Ghana
Ghana
Haiti
Kenya
Madagascar
Malawi
Malawi
Mali
Zimbabwe

Any
developmental
outcome
Any growth,
developmental, or
biomarker outcome
Infant SQ-LNS supplement

Maternal LNS
supplement
References

Results from the child-LNS-only and all-trials analyses
were similar: for nearly all outcomes, the mean differences,
prevalence ratios, and prevalence differences for intervention
against control group comparisons were almost identical or
slightly less favorable when the maternal LNS arms were
included (Supplemental Figure 2A–G). Therefore, Table 2
presents results from the all-trials analyses, inclusive of maternal
plus child LNS trials and arms. SQ-LNSs had a significant
positive effect on all primary developmental outcomes, with
effect sizes of 0.07–0.08 SD in mean language, social-emotional,
and motor scores (Table 2, Supplemental Figure 3A, B), and
relative reductions in the percentage of children in the lowest

Country

Main effects of SQ-LNSs on developmental outcomes

TABLE 1 Characteristics of trials included in the individual participant data analysis1

13 comparisons, motor outcomes for 12, social-emotional
outcomes for 11, executive function for 7, and various motor
milestones for 7–10 comparisons.
The included trials were conducted in Bangladesh (3 trials),
Burkina Faso (1 trial), Ghana (2 trials), Haiti (1 trial), Kenya
(1 trial), Madagascar (1 trial), Malawi (2 trials), Mali (1 trial),
and Zimbabwe (1 trial). Child SQ-LNS was given starting at
age 6 mo in 11 trials, 6–11 mo in 2 trials, and 9 mo in 1
trial (Table 1). Duration of supplementation ranged from 6 to
18 mo. Four trials (23, 27, 30, 31) included intervention arms
that provided SQ-LNSs to mothers during pregnancy and/or the
first 6 mo postpartum. The majority of trials provided a peanutand milk-based SQ-LNS providing ∼120 kcal/d and 1 RDA of
most micronutrients (for further details see Supplemental Table
2). Two trials targeted a subsample of children for developmental
assessment (methods described in Supplemental Table 1).
The most commonly used developmental assessment tools
were the CDI vocabulary checklist to assess language (6 trials)
(Supplemental Table 1) and the A not B task to assess executive
function (6 trials; all trials that measured executive function
used this same task). Other tools used were the Developmental
Milestones Checklist (DMC; 3 trials), Extended Ages and Stages
Questionnaire (EASQ; 2 trials), Ages and Stages Questionnaire:
Inventory (ASQ:I; 1 trial), Kilifi Development Inventory (KDI;
3 trials), Malawi Developmental Assessment Tool (MDAT; 1
trial), and Bayley Scales of Infant Development-III (BSID; 1
trial). All endline assessments were conducted when the children
were age 12–24 mo. In this age range, all of these tools assess
similar developmental skills and many items overlap between
the tools. Parent-report was used to assess social-emotional
development in all studies and to assess language in all studies
except 1. Direct child assessment was used to assess executive
function in all studies. Motor development was assessed by
parent-report in 6 studies and direct child assessment in 6 studies.
All potential study-level and individual-level effect modifiers
showed substantial variation between trials (Supplemental
Tables 3, 4). For example, at the study level, 8 study sites had a
high burden of stunting (≥35% at 18 mo) and 5 had lower rates of
stunting (<35% at 18 mo). Study-specific prevalence of improved
water quality ranged from 27% to 100%, and prevalence of
improved sanitation ranged from 0% to 97%. Frequency of
contact during the study was weekly in 7 trials and monthly
in 6 trials. Mean estimated reported compliance with SQ-LNS
consumption was categorized as high (≥80%) in 7 trials and
lower than that in the other trials.

Participants, n
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TABLE 2 Pooled fixed-effects estimates of the effect of randomized controlled trials of small-quantity lipid-based nutrient supplements provided to infants
and young children age 6–24 mo, compared with children who received no intervention or an intervention without any nutritional supplement, on
developmental outcomes1

Outcome
Continuous outcomes: MDs
Language z score MD3
Social-emotional z score MD3
Motor z score MD3
Gross motor z score MD
Fine motor z score MD
Executive function z score MD
Binary outcomes: PRs
Language lowest decile PR3
Social-emotional lowest decile PR3
Motor lowest decile PR3
Executive function lowest decile PR
12-mo milestones
Walking without support PR3
Walking with support PR
Standing without support PR
Standing with support PR
Crawling PR
18-mo milestones
Walking without support PR
Walking with support PR
Standing without support PR
Standing with support PR
Crawling PR
Binary outcomes: PDs
Language lowest decile PD
Social-emotional lowest decile PD
Motor lowest decile PD
Executive function lowest decile PD
12-mo milestones
Walking without support PD
Walking with support PD
Standing without support PD
Standing with support PD
Crawling PD
18-mo milestones
Walking without support PD
Standing without support PD
1 GRADE,

n participants
(n intervention vs. control
group comparisons)

Comparison
(95% CI)

24,561 (13)
23,588 (11)
23,899 (12)
22,871 (11)
12,460 (9)
9095 (7)

P value

Heterogeneity I2
(P-for-heterogeneity)2

Quality of the
evidence
(GRADE)

0.07 (0.04, 0.10)
0.08 (0.05, 0.11)
0.08 (0.05, 0.11)
0.06 (0.03, 0.09)
0.09 (0.04, 0.13)
0.00 (−0.04, 0.05)

<0.001
<0.001
<0.001
<0.001
0.001
0.855

0.64 (0.001)
0.66 (0.001)
0.60 (<0.001)
0.52 (<0.001)
0.00 (0.989)
0.04 (0.395)

High
High
High
High
High
High

24,561 (13)
23,588 (11)
23,899 (12)
9095 (7)

0.84 (0.76, 0.92)
0.81 (0.74, 0.89)
0.84 (0.76, 0.92)
0.93 (0.81, 1.06)

<0.001
<0.001
<0.001
0.273

0.61 (0.004)
0.54 (0.001)
0.40 (0.027)
0.16 (0.272)

High
High
High
High

13,851 (10)
13,729 (9)
13,891 (10)
13,838 (9)
13,488 (9)

1.09 (1.05, 1.14)
1.00 (1.00, 1.01)
1.03 (1.00, 1.05)
1.00 (1.00, 1.00)
1.00 (1.00, 1.01)

<0.001
0.051
0.021
0.229
0.320

0.55 (0.022)
0.41 (0.122)
0.65 (0.008)
0.00 (0.869)
0.26 (0.249)

High
High
High
High
High

6437 (7)
—
6437 (7)
—
—

1.00 (0.99, 1.01)
—
1.00 (1.00, 1.01)
—
—

0.485
—
0.207
—
—

0.28 (0.233)
—
0.00 (0.527)
—
—

High
—
High
—
—

0.005
<0.001
<0.001
0.293

0.66 (<0.001)
0.68 (0.001)
0.25 (0.195)
0.21 (0.293)

High
High
High
High

<0.001
0.039
0.006
0.211
0.267

0.57 (0.012)
0.42 (0.086)
0.56 (0.015)
0.00 (0.801)
0.22 (0.243)

High
High
High
High
High

0.40 (0.126)
0.00 (0.607)

High
High

24,561 (13)
23,588 (11)
23,899 (12)
9095 (7)

− 0.01 (−0.02, 0.00)
− 0.02 (−0.02, −0.01)
− 0.02 (−0.02, −0.01)
− 0.01 (−0.02, 0.01)

13,851 (10)
13,729 (9)
13,891 (10)
13,838 (9)
13,488 (9)

0.04 (0.02, 0.06)
0.00 (0.00, 0.01)
0.02 (0.01, 0.04)
0.00 (0.00, 0.00)
0.00 (0.00, 0.01)

6437 (7)
6437 (7)

0.00 (0.00, 0.01)
0.00 (0.00, 0.01)

Grading of Recommendations Assessment, Development and Evaluation; MD, mean difference; PD, prevalence difference; PR, prevalence

ratio.
2 I2 describes the percentage of variability in effect estimates that may be due to heterogeneity rather than chance. Roughly, 0.3–0.6 may be considered
moderate heterogeneity. P value from chi-squared test for heterogeneity. P < 0.05 indicates statistically significant evidence of heterogeneity of intervention
effects beyond chance.
3 Primary outcome.

decile of these scores ranging from 16% to 19% (Table 2, Figures
2–4). For the prevalence of children walking without support at
12 mo, there was a relative increase of 9% (4 percentage point
difference) (Table 2, Figure 5). In the JiVitA-4 trial, milestone
data were collected using monthly surveillance rather than data
collection at a single time point, the method used in all other trials.
This trial also contributed 30% of the total sample size. Therefore,
we conducted a sensitivity analysis excluding the data from this
trial and found a similar estimate of an increase of 13% (95% CI:
1.07, 1.20) in the prevalence of children walking without support
at 12 mo.

For the secondary outcomes, SQ-LNSs had a significant
positive effect on mean gross and fine motor scores of 0.06
and 0.09 SD, respectively, but no significant effect on executive
function mean or percentage in the lowest decile. Including the
effect estimates from the published report by Smuts et al. (36),
for which IPD were not available, results were similar (gross
motor: 0.06; 95% CI: 0.03, 0.09; fine motor: 0.09; 95% CI:
0.04, 0.13). For consistency with other analyses, Table 2 reports
the estimates excluding this trial by Smuts et al. Including the
JiVitA-4 data, SQ-LNSs increased the prevalence of children
standing without support at age 12 mo by 3%, and no significant
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Country

Trial

Tool

LNS
n

Control
n

PR
(95% CI)

Fixed Random
W
W

Bangladesh
Bangladesh
Bangladesh
Burkina Faso
Ghana
Ghana
Haiti
Kenya
Madagascar
Malawi
Malawi
Mali
Zimbabwe
Zimbabwe
Zimbabwe
Zimbabwe

JiVitA-4 (22)
RDNS (23)
WASH-B (24)
iLiNS-Zinc (25)
GHANA (26)
iLiNS-DYAD-G (27)
HAITI (28)
WASH-B (29)
MAHAY (30)
iLiNS-DYAD-M (31)
iLiNS-DOSE (32)
PROMIS (33)
SHINE (HIV-) (34), LNS vs. SOC
LNS+WSH vs. WSH
SHINE (HIV+) (35), LNS vs. SOC
LNS+WSH vs. WSH

BSID-III
CDI
CDI
DMC

445
1663
1109
746

143
814
3353
375

0.86 (0.50, 1.49)
0.72 (0.57, 0.91)
0.81 (0.65, 1.00)
0.46 (0.33, 0.64)

0.03
0.15
0.18
0.08

0.06
0.10
0.10
0.09

CDI
Total sounds
EASQ
ASQ:I
CDI
CDI
DMC
CDI
CDI
CDI
CDI

331
150
1362
1613
215
645
927
381
436
66
99

658
149
4745
1604
439
221
944
373
408
68
79

1.09 (0.74, 1.61)
2.75 (1.28, 5.93)
0.95 (0.78, 1.16)
1.17 (0.75, 1.83)
0.87 (0.53, 1.43)
0.95 (0.61, 1.50)
0.77 (0.56, 1.07)
1.05 (0.67, 1.65)
0.77 (0.49, 1.20)
1.29 (0.54, 3.06)
0.32 (0.11, 0.92)

0.05
0.01
0.21
0.04
0.03
0.04
0.08
0.08
0.08
0.02
0.02

0.08
0.04
0.11
0.07
0.06
0.07
0.09
0.09
0.09
0.05
0.05

I² = 0.61, Tau² = 0.07
Fixed
Random

10,188 14,373
0.84 (0.76, 0.92)
0.87 (0.72, 1.04)
0.25

0.50

1.0
Ratio

Favors LNS

2.0

4.0

Favors Control

FIGURE 2 Forest plot of the effect of small-quantity LNSs on the prevalence of children in the lowest decile of language scores. Individual study estimates
were generated from log-binomial regression controlling for baseline measure when available and with clustered observations using robust SEs for clusterrandomized trials. Pooled estimates were generated using inverse-variance weighting in both fixed- and random-effects models. Individual trial estimates
for the SHINE trial are split by comparison in the figure to reflect the crossover design. For calculating the pooled estimates, the trial was analyzed with
LNS intervention arms combined and non-LNS intervention arms combined. ASQ:I, Ages and Stages Questionnaire Inventory; BSID, Bayley Scales of Infant
Development; CDI, MacArthur-Bates Communicative Development Inventory; DMC, Developmental Milestones Checklist; EASQ, Extended Ages and Stages
Questionnaire; LNS, lipid-based nutrient supplement; PR, prevalence ratio; SOC, standard of care; WSH, water, sanitation, and hygiene intervention.

Country

Trial

Tool

LNS Control
n
n

PR
(95% CI)

Fixed Random
W
W

Bangladesh
Bangladesh
Bangladesh
Burkina Faso
Ghana
Ghana
Haiti
Kenya
Madagascar
Malawi
Malawi
Mali
Zimbabwe
Zimbabwe
Zimbabwe
Zimbabwe

JiVitA-4 (22)
RDNS (23)
WASH-B (24)
iLiNS-Zinc (25)
GHANA (26)
iLiNS-DYAD-G (27)
HAITI (28)
WASH-B (29)
MAHAY (30)
iLiNS-DYAD-M (31)
iLiNS-DOSE (32)
PROMIS (33)
SHINE (HIV-) (34), LNS vs. SOC
LNS+WSH vs. WSH
SHINE (HIV+) (35), LNS vs. SOC
LNS+WSH vs. WSH

BSID-III
DMC
EASQ
DMC

445
1556
1074
746

143
753
3279
375

1.26 (0.77, 2.07)
0.85 (0.67, 1.07)
0.82 (0.66, 1.01)
0.49 (0.36, 0.67)

0.03
0.15
0.19
0.09

0.05
0.13
0.14
0.10

KDI

302

601

1.13 (0.76, 1.70)

0.05

0.07

EASQ
ASQ:I
KDI
KDI
DMC
MDAT
MDAT
MDAT
MDAT

1362
1613
214
646
902
395
446
67
103

4745
1604
436
221
921
382
417
68
83

0.86 (0.70, 1.05)
0.91 (0.58, 1.44)
0.84 (0.51, 1.40)
1.08 (0.67, 1.71)
0.81 (0.56, 1.18)
1.08 (0.67, 1.73)
0.82 (0.54, 1.24)
1.16 (0.44, 3.08)
0.40 (0.17, 0.95)

0.21
0.04
0.03
0.04
0.06
0.09
0.09
0.02
0.02

0.14
0.06
0.05
0.06
0.08
0.10
0.10
0.03
0.03

I² = 0.40, Tau² = 0.02
Fixed
Random

9871 14,028
0.84 (0.76, 0.92)
0.85 (0.74, 0.97)
0.25

0.50

Favors LNS

1.0
Ratio

2.0

4.0

Favors Control

FIGURE 4 Forest plot of the effect of small-quantity LNSs on the prevalence of children in the lowest decile of motor scores. Individual study estimates
were generated from log-binomial regression controlling for baseline measure when available and with clustered observations using robust SEs for clusterrandomized trials. Pooled estimates were generated using inverse-variance weighting in both fixed- and random-effects models. Individual trial estimates for
the SHINE trial are split by comparison in the figure to reflect the crossover design. For calculating the pooled estimates, the trial was analyzed with LNS
intervention arms combined and non-LNS intervention arms combined. ASQ:I, Ages and Stages Questionnaire Inventory; BSID, Bayley Scales of Infant
Development; DMC, Developmental Milestones Checklist; EASQ, Extended Ages and Stages Questionnaire; KDI, Kilifi Developmental Inventory; LNS,
lipid-based nutrient supplement; MDAT, Malawi Developmental Assessment Tool; PR, prevalence ratio; SOC, standard of care; WSH, water, sanitation, and
hygiene intervention.
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Country

Trial

Bangladesh
Bangladesh
Bangladesh
Burkina Faso
Ghana
Ghana
Haiti
Kenya
Madagascar
Malawi
Malawi
Mali
Zimbabwe
Zimbabwe

JiVitA-4 (22)
RDNS (23)
WASH-B (24)
iLiNS-Zinc (25)
GHANA (26)
iLiNS-DYAD-G (27)
HAITI (28)
WASH-B (29)
MAHAY (30)
iLiNS-DYAD-M (31)
iLiNS-DOSE (32)
PROMIS (33)
SHINE (HIV-) (34)
SHINE (HIV+) (35)

LNS Control
n
n

PR
(95% CI)

Fixed Random
W
W

3014 1363
1628 790
497 1474

1.05 (0.99, 1.12)
1.28 (1.07, 1.53)
1.20 (1.05, 1.38)

0.46
0.06
0.10

0.16
0.11
0.13

90
327
83
447

87
663
79
1604

1.67 (1.08, 2.58)
1.15 (1.01, 1.31)
1.25 (0.86, 1.81)
0.97 (0.85, 1.10)

0.01
0.11
0.01
0.12

0.04
0.13
0.05
0.13

208
602
118

426
200
151

1.20 (1.03, 1.40)
1.04 (0.84, 1.30)
0.70 (0.44, 1.11)

0.08
0.04
0.01

0.12
0.09
0.03

I² = 0.55, Tau² = 0.01 7014 6837
Fixed
Random

1.09 (1.05, 1.14)
1.12 (1.02, 1.24)
0.50

1.0
Ratio

Favors Control

2.0
Favors LNS

FIGURE 5 Forest plot of the effect of SQ-LNSs on the prevalence of children walking without support at age 12 mo. Individual study estimates were
generated from log-binomial regression controlling for baseline measure when available and with clustered observations using robust SEs for cluster-randomized
trials. Pooled estimates were generated using inverse-variance weighting in both fixed- and random-effects models. LNS, lipid-based nutrient supplement; PR,
prevalence ratio.

effects were found on any other milestones examined (Table 2).
Excluding the JiVitA-4 data, SQ-LNSs increased the prevalence
of children standing without support at age 12 mo by 6% (95%
CI: 1.02, 1.08). Pooled estimates were not generated for 3 of
the 5 milestones at 18 mo owing to lack of variance, because
almost all children had attained the milestones by this age (see
Supplemental Table 5 for the percentage of children in the
control arms who attained each milestone at 12 and 18 mo in each
trial).
Supplemental Figure 2A–G shows the results of all 8 analyses,
that is, fixed- and random-effects models for each of the 1)
all-trials analysis, 2) child-LNS-only analysis, 3) sensitivity
analysis excluding passive arms, and 4) sensitivity analysis
separating multicomponent arms to compare only pairs of arms
that included the same nonnutrition components. Results were
similar regardless of whether fixed-effects or random-effects
models were used, although CIs were wider for the latter, as
expected. Results were also similar in the sensitivity analyses. For
example, across the 8 analyses, effect sizes on language scores
ranged from 0.05 to 0.09 and reductions in the percentage of
children in the lowest decile of language ranged from 11% to
20%.
In addition, effects of SQ-LNSs on the prevalence in the
lowest decile of motor and social-emotional scores were evident
in both the studies implemented through existing programs and
those implemented by the research teams, although effects on
language were smaller in studies implemented through existing
programs (Supplemental Figure 4A–C). Effects were also
evident when stratified by whether the trial reinforced the normal

IYCF messages already promoted in that setting, or the trial
provided expanded behavior change communication for IYCF
in the SQ-LNS intervention arms. Effects on motor and socialemotional development were slightly smaller in the trials that
provided expanded IYCF messages in both the intervention and
control arms; however, there were only 2–3 trials in this group
(Supplemental Figure 5A–C).
Risk of bias and quality of evidence
In general, we rated individual trials as having low risk of bias,
except for the lack of blinding of participants due to the nature
of the intervention. Because of the latter, outcome assessment
was not blinded when development was assessed by parent-report
(language and social-emotional outcomes in most trials and
motor outcomes in half of the trials) (Supplemental Table 6A–
M, Supplemental Figure 1). In analyses that included a subset of
studies, there was a mix of high and low child stunting burden and
maternal educational levels among both the included studies and
the excluded studies, with the following exceptions. For socialemotional outcomes, all of the 4 excluded studies were among the
7 studies in the category for higher maternal education (>50%
completed primary). For motor outcomes, all of the 3 excluded
studies were in the category for higher maternal education.
For all developmental outcomes, we rated the overall quality
of evidence as high. All included studies were randomized
controlled trials, therefore GRADE ratings started as high and
we did not downgrade the quality of the evidence based on the
following 5 criteria. 1) Heterogeneity across trials was low to
moderate (I2 = 0.00–0.60) for 20 outcomes and substantial (I2
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Country

Trial

Bangladesh
Bangladesh
Bangladesh
Burkina Faso
Ghana
Ghana
Haiti
Kenya
Madagascar
Malawi
Malawi
Mali
Zimbabwe
Zimbabwe
Zimbabwe
Zimbabwe

JiVitA-4 (22)
RDNS (23)
WASH-B (24)
iLiNS-Zinc (25)
GHANA (26)
iLiNS-DYAD-G (27)
HAITI (28)
WASH-B (29)
MAHAY (30)
iLiNS-DYAD-M (31)
iLiNS-DOSE (32)
PROMIS (33)
SHINE (HIV-) (34), LNS vs. SOC
LNS+WSH vs. WSH
SHINE (HIV+) (35), LNS vs. SOC
LNS+WSH vs. WSH

I² = 0.54, Tau² = 0.06
Fixed
Random

PR
(95% CI)

Fixed Random
W
W

DMC 1657 815
EASQ 1066 3266
DMC 746 375

0.84 (0.66, 1.07)
0.81 (0.64, 1.03)
0.41 (0.28, 0.62)

0.16
0.17
0.06

0.12
0.12
0.08

PSED 332

657

0.99 (0.67, 1.47)

0.06

0.09

EASQ
ASQ:I
PSED
PSED
DMC
MDAT
MDAT
MDAT
MDAT

4745
1604
438
221
944
382
417
68
83

0.87 (0.71, 1.08)
1.15 (0.75, 1.78)
1.00 (0.61, 1.61)
1.08 (0.68, 1.72)
0.77 (0.56, 1.07)
0.86 (0.56, 1.33)
0.62 (0.41, 0.93)
0.68 (0.22, 2.04)
0.33 (0.15, 0.76)

0.21
0.05
0.04
0.04
0.09
0.10
0.10
0.02
0.02

0.12
0.08
0.07
0.07
0.10
0.10
0.10
0.05
0.05

Tool

LNS Control
n
n

1362
1613
215
644
927
395
446
67
103

9573 14, 015
0.81 (0.74, 0.89)
0.80 (0.67, 0.96)
0.25

0.50

Favors LNS

1.0
Ratio

2.0

4.0

Favors Control

FIGURE 3 Forest plot of the effect of small-quantity LNSs on the prevalence of children in the lowest decile of social-emotional scores. Individual study
estimates were generated from log-binomial regression controlling for baseline measure when available and with clustered observations using robust SEs for
cluster-randomized trials. Pooled estimates were generated using inverse-variance weighting in both fixed- and random-effects models. Individual trial estimates
for the SHINE trial are split by comparison in the figure to reflect the crossover design. For calculating the pooled estimates, the trial was analyzed with LNS
intervention arms combined and non-LNS intervention arms combined. ASQ:I, Ages and Stages Questionnaire Inventory; DMC, Developmental Milestones
Checklist; EASQ, Extended Ages and Stages Questionnaire; LNS, lipid-based nutrient supplement; MDAT, Malawi Developmental Assessment Tool; PR,
prevalence ratio; PSED, Profile of Social and Emotional Development; SOC, standard of care; WSH, water, sanitation, and hygiene intervention.

= 0.61–0.68) for 5 outcomes (Table 2), therefore, inconsistency
was not considered high enough to downgrade the quality of
the evidence. 2) Precision was rated as high because all but
2 trials had sample sizes >600. 3) Directness was high because
all trials were directly aimed at evaluating SQ-LNSs. 4) Funnel
plots revealed no indication of publication bias across studies. 5)
We did not consider risk of bias in individual studies high enough
to downgrade the quality of the evidence. As aforementioned,
the main potential source of bias was the lack of participant
blinding and therefore the lack of blinding of outcome assessment
when development was assessed by parent-report. Parent-report
methods were used for language and social-emotional outcomes
in most trials and motor outcomes in half of the trials. To
explore this potential bias, we calculated pooled effect sizes
for motor outcomes stratified by parent-report compared with
directly observed assessments and found that effects of SQ-LNSs
were larger among studies that used parent-report (0.13; 95% CI:
0.02, 0.23; 6 comparisons; compared with 0.07; 95% CI: −0.01,
0.15; 6 comparisons for direct child observation). However,
3 studies included in this IPD meta-analysis used direct
observation for at least a subgroup of items or children to check
the validity of the parent-report assessments and found similar
intervention effects on observed motor and language outcomes
compared with the corresponding parent-report outcomes (28,
43, 45). Although the parents may have reported more accurately
because they knew their children were also being observed,
the assessment methods were substantially different (e.g., a

parent-report vocabulary checklist compared with the observed
MDAT language subscale which assesses many different types
of language skills). Thus, this consistency suggests that reporting
bias did not account for the effects of SQ-LNSs, at least in those
3 trials. Given this evidence and given that the pooled effect size
on observed motor outcomes (0.07) was in the same range as
all primary outcome pooled effect sizes (0.06–0.08), we did not
consider that this risk of bias was high enough to downgrade our
confidence in the accuracy of the pooled estimates.
Effect modification by study-level characteristics
Study-level effect modification results were consistent across
all fixed- and random-effects analyses and across all sensitivity
analyses (data not shown, available on request). The results
presented below refer to the fixed-effects all-trials analysis.
For some outcomes, we were unable to generate pooled
estimates for effect modification by certain potential study-level
effect modifiers because <3 comparisons were categorized into
1 of the study-level effect modification categories (e.g., socialemotional development by geographic region). We were unable
to examine potential effect modification by child age at baseline
because there was insufficient heterogeneity in this aspect of
study design: most of the trials began supplementation at 6 mo of
age.
The study-level stunting burden significantly modified the
effect of SQ-LNSs on language, social-emotional, motor, and
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gross motor development. Among studies with higher 18-mo
stunting burden in the control group (≥35%), effects on these
developmental scores ranged from 0.08 to 0.13 SD, whereas
effect sizes among studies with lower stunting burden (<35%)
were 0.01 SD (Table 3, Figure 6). There was also a greater
reduction in the prevalence of children in the lowest decile
of language scores among studies with higher stunting burden
(Table 4).
Anemia prevalence among children age 6–59 mo modified the
effect of SQ-LNSs on the prevalence of children in the lowest
decile of motor scores. In countries with ≥60% child anemia
prevalence, SQ-LNSs reduced this adverse motor outcome by
25%, compared with a 12% reduction in countries with <60%
anemia prevalence (Table 4).
Study-level sanitation (<50% compared with ≥50% prevalence of improved sanitation in the study sample) modified the
effect of SQ-LNSs on executive function (Table 3). Among the
3 comparisons with higher prevalence of improved sanitation, the
pooled effect of SQ-LNSs on executive function was 0.06 SD
(95% CI: −0.01, 0.13 SD), whereas among the 4 comparisons
with a lower prevalence of improved sanitation, the pooled
effect size was −0.09 SD (95% CI: −0.18, 0.01 SD). No
other study-level characteristics significantly modified effects of
SQ-LNSs on any other developmental outcome (Supplemental
Figure 6A–P).

Effect modification by individual-level characteristics
Individual-level effect modification results were consistent
across fixed- and random-effects models and across all sensitivity
analyses (data not shown; available upon request). The results
presented below refer to the fixed-effects all-trials analysis. The
following individual-level characteristics did not significantly
modify the effect of SQ-LNSs on any developmental outcome:
indicators of household food insecurity, water quality, sanitation,
and home environment; maternal BMI and depressive symptoms;
child sex; and season at outcome assessment (Tables 5, 6,
Supplemental Figures 7, 8).
Household socioeconomic status (SES; above or below the
study median) modified the effect of SQ-LNSs on mean language,
motor, and executive function scores (Table 5, Figure 7). Effects
of SQ-LNSs on these scores were larger among children in lowSES households (0.06–0.12 SD) than among children in highSES households (−0.04 to 0.05 SD). For the percentage of
children in the lowest decile of scores, there was no significant
effect modification by household SES with regard to prevalence
ratios. However, for language there was a greater percentage point
reduction in low scores among children in the low-SES group
(3 percentage points) than in the high-SES group (1 percentage
point) (Supplemental Figure 8C).
Child baseline acute malnutrition [weight-for-length z score
(WLZ) < −2 SD or midupper arm circumference (MUAC) <
125 mm] modified the effect of SQ-LNSs on mean language
scores (Table 5, Figure 8). The effect of SQ-LNSs on mean
language score was significantly larger among children who
were malnourished when they began receiving SQ-LNSs
(0.30 SD) than among those who were not (0.11 SD). Socialemotional and motor scores showed a similar pattern of greater
effect sizes among acutely malnourished children (0.27 SD for
both outcomes compared with 0.09–0.10 SD among children

who were not malnourished); however, the interaction tests were
not statistically significant.
Child baseline stunting (LAZ < −2 SD) modified the effect
of SQ-LNSs on the prevalence difference of children in the
lowest decile of language scores. There was a 7 percentage point
reduction of children in the lowest decile of language scores
among children who were stunted when they began receiving SQLNSs (95% CI: −0.11, −0.04), compared with a 3 percentage
point reduction (95% CI: −0.04, −0.01) (Supplemental Figure
7C8) among those who were not stunted. Social-emotional and
motor scores showed similar trends of greater effect sizes among
stunted children (Figure 9); however, no interactions between
baseline stunting and intervention group were significant for
these or any other outcomes.
Maternal education, maternal age, and child birth order
modified the effects of SQ-LNSs on mean motor and fine motor
scores (Table 5). Greater effects of SQ-LNSs on these scores
were found among children of mothers with lower education
(0.11–0.14 SD) than those with higher education (0.05–0.06 SD),
among children of older mothers (0.10–0.14 SD) than younger
mothers (0.03–0.07 SD), and among later-born children (i.e.,
those born after the firstborn child; 0.11–0.12 SD) than firstborn
children (0.03–0.04 SD). Maternal education also modified the
effects of SQ-LNSs with respect to the prevalence difference
for scoring in the lowest decile of motor scores, with greater
reductions among children of mothers with lower education
(Supplemental Figure 7I4). Birth order also modified the effect
of SQ-LNSs on this adverse motor outcome, with a greater
reduction among later-born children (24% reduction compared
with 1% increase among firstborn children), and on walking
without support at 12 mo, with a greater positive effect among
later-born children (16% increase compared with 5% increase
among firstborn children) (Table 6). Maternal age also modified
the effect of SQ-LNSs on the prevalence of children in the lowest
decile of executive function scores. In contrast to the pattern for
motor scores, for executive function greater effects with respect
to both the prevalence ratio and the prevalence difference were
found among children of younger mothers than among children of
older mothers (Table 6; Supplemental Figure 7M3, N3). Maternal
education, maternal age, and birth order did not modify the effects
of SQ-LNSs on any other developmental outcomes.
Maternal height and child baseline anemia modified the effect
of SQ-LNSs on mean fine motor scores, but no other outcomes.
There were greater effects of SQ-LNSs on fine motor scores
among children of taller mothers (0.09 SD) than children of
shorter mothers (0.04 SD) and children who were anemic at baseline (0.13 SD) than children who were not (−0.01 SD) (Table 5).

Discussion
In this IPD meta-analysis of 13 randomized controlled trials
in 9 countries with a total sample size of >30,000 children,
SQ-LNSs provided to infants and young children 6–24 mo
of age increased mean language, social-emotional, and motor
scores by 0.06–0.09 SD and led to a relative reduction of 16%–
19% in adverse developmental outcomes (1–2 percentage point
difference). The quality of the evidence for all outcomes was
high. The effects of SQ-LNSs on developmental outcomes did not
significantly differ by most study-level characteristics including
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1 comp, number of intervention against control group comparisons; MD, mean difference in random-effects models; n, number of individual participants; P-diff, P value for the difference in effects of small-quantity lipid-based nutrient supplements between the 2 levels of the
effect modifier in random-effects models; SQ-LNS, small-quantity lipid-based nutrient supplement.

Geographic region
Africa
Southeast Asia
18-mo stunting burden, %
<35
≥35
Malaria prevalence, %
<10
≥10
Anemia prevalence, %
<60
≥60
Source water quality
<75% improved
≥75% improved
Sanitation
<50% improved
≥50% improved
Supplement duration, mo
≤12
>12
Frequency of contact
Weekly
Monthly
Mean SQ-LNS compliance, %
<80
≥80

n (comp)

Language

TABLE 3 Study-level effect modifiers of effects of SQ-LNSs provided to infants and young children age 6–24 mo on continuous developmental outcomes1

SQ-LNS IPD meta-analysis: development
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Supplement
Effect modifier
(P-diff)

LNS Control
n
n

Language (P = 0.077)
2058
Stunting <35%
8130
Stunting >35%
Social-Emotional (P = 0.066)
1909
Stunting <35%
7664
Stunting >35%
Motor (P = 0.045)
1878
Stunting <35%
7993
Stunting >35%
Fine motor (P = 0.481)
516
Stunting <35%
6261
Stunting >35%
Gross motor (P = 0.014)
1878
Stunting <35%
7299
Stunting >35%
Executive function (P = 0.648)
472
Stunting <35%
3049
Stunting >35%

Mean difference
(95% CI)

5991
8382

0.01 (-0.04, 0.06)
0.11 (0.02, 0.20)

5840
8175

0.01 (-0.04, 0.07)
0.13 (0.04, 0.23)

5782
8246

0.01 (-0.04, 0.07)
0.13 (0.05, 0.21)

1037
4646

0.05 (-0.04, 0.15)
0.10 (0.04, 0.15)

5782
7912

0.01 (-0.05, 0.06)
0.08 (0.01, 0.16)

945
4629

-0.02 (-0.13, 0.09)
0.01 (-0.06, 0.07)
-0.4

0
Difference
Favors Control

0.4
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FIGURE 6 Pooled effects of SQ-LNSs on all continuous developmental outcomes stratified by study-level stunting burden of children at age 18 mo in
control groups. Individual study estimates for interaction effect were generated from log-binomial regression controlling for baseline measure when available
and with clustered observations using robust SEs for cluster-randomized trials. Pooled subgroup estimates and statistical testing of the pooled interaction
term were generated using inverse-variance weighting random effects. LNS, lipid-based nutrient supplement; P-diff, P value for the difference in effects of
small-quantity lipid-based nutrient supplements between the 2 levels of the effect modifier.

region (although most studies were conducted in Sub-Saharan
Africa), malaria prevalence, water quality, supplementation
duration, frequency of contact, or mean compliance with SQLNSs, indicating that these aspects of context and program
delivery did not explain differences in effect sizes across these
13 trials. However, effects of SQ-LNSs on language, socialemotional, and motor development were larger among study
populations with a higher stunting burden and effects on motor
development were larger in sites with higher prevalence of child
anemia. At the individual level, greater effects of SQ-LNSs
were found on language among children who were stunted or
acutely malnourished when they started receiving SQ-LNSs;
on language, motor, and executive function among households
with lower SES; and on motor and fine motor development
among later-born children, children of older mothers, and
children of mothers with lower education. Children of taller
mothers and children who were anemic at baseline also showed
greater effects on fine motor scores, whereas children of
younger mothers showed greater effects on executive function
scores.

Main effects
Our findings of significant positive effects of SQ-LNSs on
developmental outcomes in the range of 0.06–0.09 SD, which
would be analogous to ∼1–1.5 IQ points on an IQ test, are
consistent with a previous meta-analysis of SQ-LNSs by Tam

et al. (7), which reported slightly larger effect sizes of 0.12–
0.13 SD (∼1.8–2 IQ points). Effect sizes in the range of 0.06–
0.09 SD are probably more accurate for a general population, because our analysis included a larger number of trials
(13 compared with 6) and children (∼30,000 compared with
∼3500). However, we found effect sizes closer to their estimates
in sites with a higher stunting burden (0.11–0.13 SD), and the
trials included in the Tam et al. meta-analysis tended to have
a high stunting burden. These effect sizes are also consistent
with previous meta-analyses of child nutritional supplementation
trials in LMICs. A meta-analysis by Larson and Yousafzai (48)
of 23 nutritional supplementation randomized controlled trials
among children age 0–2 y indicated an effect size of 0.08 SD for
cognitive/mental development. Another meta-analysis by Prado
et al. (49) of effects of interventions from pregnancy to 5 y
on linear growth and development showed an effect of child
nutritional supplementation of 0.13 SD on language (13 studies),
0.09 SD on motor (27 studies), and 0.09 SD on social-emotional
development (13 studies).
These previous meta-analyses pooled effects across studies
that provided a wide range of different types of nutritional
supplements, including single micronutrients, as well as multiple
micronutrients with and without macronutrients. Few previous
meta-analyses of specific types of nutritional supplements
have been able to calculate pooled effects on developmental
outcomes, owing to small numbers of studies and differences
in measurement and reporting of outcomes in this domain.
For example, a 2020 Cochrane review of home fortification
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6204 (6)
14,478 (5)

8482 (6)
15,417 (6)

9307 (8)
14,592 (4)

9489 (7)
7250 (5)

9795 (6)
6944 (6)

19,438 (8)
4461 (4)

18,535 (7)
5364 (5)

7660 (3)
16,239 (9)

16,649 (9)
7250 (3)

n (comp)

0.92 (0.78, 1.09)
0.92 (0.78, 1.09)

P-diff: 0.610
0.83 (0.70, 0.98)
0.88 (0.72, 1.08)
P-diff: 0.466
0.90 (0.76, 1.07)
0.83 (0.70, 0.98)
P-diff: 0.491
0.87 (0.78, 0.97)
0.82 (0.60, 1.10)
P-diff: 0.093
0.88 (0.79, 0.98)
0.75 (0.54, 1.05)
P-diff: 0.303
0.82 (0.64, 1.05)
0.93 (0.80, 1.08)
P-diff: 0.599
0.85 (0.68, 1.08)
0.90 (0.77, 1.05)
P-diff: 0.839
0.87 (0.69, 1.08)
0.84 (0.74, 0.94)
P-diff: 0.977
0.87 (0.66, 1.15)
0.86 (0.76, 0.97)
P-diff: 0.330

Pooled PR
(95% CI)

Motor lowest decile

2695 (4)
11,156 (6)

8951 (6)
4900 (4)

7142 (6)
6709 (4)

2344 (3)
9117 (7)

1177 (2)
10,284 (8)

11,807 (5)
2044 (5)

10,979 (5)
2872 (5)

4014 (5)
9837 (5)

4923 (6)
8766 (3)

n (comp)

1.08 (0.90, 1.29)
1.08 (0.90, 1.29)

P-diff: 0.525
1.09 (0.91, 1.30)
1.15 (1.02, 1.29)
P-diff: 0.711
1.15 (1.00, 1.33)
1.09 (0.94, 1.27)
P-diff: 0.768
1.11 (1.00, 1.23)
1.12 (0.90, 1.41)
P-diff: 0.720
1.11 (1.01, 1.22)
1.14 (0.89, 1.45)
P-diff: —
—
1.14 (1.07, 1.23)
P-diff: 0.631
1.10 (0.98, 1.24)
1.15 (1.00, 1.33)
P-diff: 0.618
1.13 (1.03, 1.23)
1.06 (0.85, 1.34)
P-diff: 0.433
1.14 (1.05, 1.23)
1.05 (0.83, 1.34)
P-diff: 0.700

Pooled PR
(95% CI)

Walking without support at 12 mo

1
comp, number of intervention against control group comparisons; n, number of individual participants; P-diff, P value for the difference in effects of small-quantity lipid-based nutrient supplements between the 2 levels of the effect
modifier in random-effects models; PR, prevalence ratio in random-effects models; SQ-LNS, small-quantity lipid-based nutrient supplement.

Geographic region
Africa
Southeast Asia
18-mo stunting burden, %
<35
≥35
Malaria prevalence, %
<10
≥10
Anemia prevalence, %
<60
≥60
Source water quality
<75% improved
≥75% improved
Sanitation
<50% improved
≥50% improved
Supplement duration, mo
≤12
>12
Frequency of contact
Weekly
Monthly
Mean SQ-LNS compliance,
%
<80
≥80

n (comp)

Language lowest decile

TABLE 4 Study-level effect modifiers of effects of SQ-LNSs provided to infants and young children age 6–24 mo on binary developmental outcomes1
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19,158 (10)

19,878 (8)

13,484 (11)

12,608 (9)

21,412 (11)

24,207 (13)

4231 (5)

7974 (8)

8256 (9)

24,165 (13)

24,561 (13)

17,607 (8)

24,416 (13)

24,259 (13)

19,713 (10)

23,010 (11)

P-int: 0.857
0.08 (0.01, 0.15)
0.08 (0.04, 0.11)
P-int: 0.194
0.10 (0.04, 0.15)
0.09 (0.05, 0.14)
P-int: 0.361
0.07 (0.03, 0.11)
0.09 (0.05, 0.14)
P-int: 0.411
0.07 (0.03, 0.12)
0.06 (0.02, 0.10)
P-int: 0.950
0.06 (0.02, 0.11)
0.06 (−0.01, 0.13)
P-int: 0.424
0.05 (0.01, 0.10)
0.09 (0.05, 0.14)
P-int: 0.519
0.05 (0.00, 0.11)
0.08 (0.04, 0.12)
P-int: 0.255
0.19 (0.08, 0.30)
0.09 (0.03, 0.14)
P-int: 0.034
0.31 (0.17, 0.44)
0.11 (0.06, 0.16)
P-int: 0.650
0.17 (0.08, 0.26)
0.08 (−0.03, 0.20)
P-int: 0.001
0.12 (0.08, 0.17)
0.03 (−0.01, 0.07)
P-int: 0.627
0.10 (0.04, 0.17)
0.06 (0.03, 0.10)
P-int: 0.988
0.11 (0.03, 0.18)
0.10 (0.04, 0.16)
P-int: 0.218
0.10 (0.04, 0.15)
0.12 (0.06, 0.17)
P-int: 0.251
0.07 (0.01, 0.12)
0.05 (0.01, 0.10)
P-int: 0.979
0.09 (0.04, 0.13)
0.07 (0.02, 0.12)

Pooled MD
(95% CI)

18,484 (9)

19,742 (8)

12,894 (10)

12,610 (9)

20,737 (10)

23,263 (11)

4228 (5)

7412 (7)

7396 (7)

23,201 (11)

23,588 (11)

17,523 (8)

23,441 (11)

23,289 (11)

19,626 (10)

22,926 (11)

n (comp)
P-int: 0.511
0.09 (0.03, 0.16)
0.07 (0.03, 0.10)
P-int: 0.885
0.09 (0.03, 0.14)
0.08 (0.04, 0.12)
P-int: 0.666
0.10 (0.05, 0.14)
0.07 (0.02, 0.11)
P-int: 0.700
0.05 (0.00, 0.10)
0.09 (0.05, 0.13)
P-int: 0.335
0.08 (0.04, 0.12)
0.03 (−0.04, 0.10)
P-int: 0.706
0.08 (0.04, 0.13)
0.07 (0.03, 0.12)
P-int: 0.979
0.09 (0.03, 0.14)
0.07 (0.03, 0.11)
P-int: 0.495
0.14 (0.03, 0.25)
0.09 (0.04, 0.15)
P-int: 0.349
0.28 (0.12, 0.43)
0.10 (0.05, 0.16)
P-int: 0.834
0.12 (0.03, 0.22)
0.08 (−0.03, 0.19)
P-int: 0.982
0.08 (0.03, 0.12)
0.07 (0.03, 0.12)
P-int: 0.347
0.07 (0.01, 0.13)
0.08 (0.04, 0.12)
P-int: 0.939
0.09 (0.01, 0.16)
0.11 (0.05, 0.16)
P-int: 0.550
0.07 (0.01, 0.13)
0.11 (0.05, 0.17)
P-int: 0.363
0.06 (0.00, 0.11)
0.04 (0.00, 0.08)
P-int: 0.734
0.10 (0.06, 0.15)
0.06 (0.01, 0.10)

Pooled MD
(95% CI)

Social-emotional

9088 (7)

7274 (5)

5097 (7)

3508 (5)

8842 (7)

8894 (7)

2662 (4)

4161 (6)

4148 (6)

8811 (7)

9095 (7)

8129 (6)

8972 (7)

8870 (7)

8712 (7)

8959 (7)

n (comp)
P-int: 0.522
− 0.02 (−0.11, 0.07)
0.01 (−0.05, 0.06)
P-int: 0.888
0.01 (−0.06, 0.09)
0.00 (−0.06, 0.06)
P-int: 0.470
0.03 (−0.04, 0.09)
− 0.02 (−0.09, 0.04)
P-int: 0.495
− 0.01 (−0.10, 0.08)
0.01 (−0.05, 0.06)
P-int: 0.332
0.02 (−0.03, 0.08)
− 0.03 (−0.12, 0.07)
P-int: 0.414
0.01 (−0.05, 0.08)
− 0.01 (−0.07, 0.05)
P-int: 0.285
0.04 (−0.04, 0.12)
− 0.02 (−0.07, 0.04)
P-int: 0.702
− 0.04 (−0.19, 0.11)
0.01 (−0.07, 0.08)
P-int: 0.166
0.16 (−0.10, 0.43)
− 0.01 (−0.07, 0.06)
P-int: 0.567
0.02 (−0.10, 0.13)
− 0.01 (−0.12, 0.10)
P-int: 0.033
0.06 (−0.01, 0.12)
− 0.04 (−0.10, 0.03)
P-int: 0.984
0.01 (−0.07, 0.09)
0.01 (−0.05, 0.06)
P-int: 0.700
− 0.01 (−0.18, 0.17)
− 0.01 (−0.09, 0.06)
P-int: 0.947
− 0.04 (−0.14, 0.05)
0.04 (−0.03, 0.11)
P-int: 0.142
− 0.06 (−0.14, 0.02)
0.03 (−0.03, 0.09)
P-int: 0.766
− 0.01 (−0.07, 0.05)
0.02 (−0.05, 0.09)

Pooled MD
(95% CI)

Executive function

18,843 (10)

19,514 (8)

13,187 (11)

12,561 (9)

21,094 (11)

23,572 (12)

4119 (5)

7765 (8)

7749 (8)

23,508 (12)

23,899 (12)

17,302 (8)

23,751 (12)

23,597 (12)

19,362 (10)

22,662 (11)

n (comp)

Pooled MD
(95% CI)
P-int: 0.457
0.09 (0.03, 0.16)
0.09 (0.05, 0.12)
P-int: 0.553
0.12 (0.06, 0.17)
0.07 (0.03, 0.11)
P-int: 0.043
0.07 (0.03, 0.11)
0.10 (0.06, 0.15)
P-int: 0.015
0.11 (0.06, 0.16)
0.06 (0.02, 0.09)
P-int: 0.823
0.07 (0.03, 0.11)
0.07 (0.01, 0.12)
P-int: 0.754
0.08 (0.04, 0.12)
0.09 (0.05, 0.13)
P-int: 0.042
0.03 (−0.03, 0.08)
0.11 (0.07, 0.15)
P-int: 0.207
0.16 (0.06, 0.26)
0.08 (0.04, 0.13)
P-int: 0.131
0.28 (0.12, 0.44)
0.09 (0.05, 0.14)
P-int: 0.369
0.16 (0.08, 0.24)
0.06 (−0.05, 0.16)
P-int: 0.077
0.11 (0.07, 0.16)
0.05 (0.01, 0.09)
P-int: 0.898
0.11 (0.05, 0.17)
0.07 (0.04, 0.11)
P-int: 0.514
0.17 (0.09, 0.25)
0.09 (0.03, 0.15)
P-int: 0.193
0.07 (0.02, 0.13)
0.11 (0.06, 0.16)
P-int: 0.565
0.05 (−0.01, 0.11)
0.07 (0.04, 0.11)
P-int: 0.827
0.09 (0.05, 0.14)
0.08 (0.04, 0.12)

Motor

7403 (7)

8074 (5)

7937 (8)

7104 (6)

9665 (8)

12,138 (9)

3029 (4)

6774 (7)

6759 (7)

12,197 (9)

12,460 (9)

7433 (6)

12,319 (9)

12,229 (9)

8234 (7)

11,533 (8)

n (comp)
P-int: 0.069
0.04 (−0.06, 0.13)
0.09 (0.04, 0.14)
P-int: 0.767
0.10 (0.01, 0.19)
0.09 (0.03, 0.15)
P-int: 0.005
0.03 (−0.03, 0.10)
0.14 (0.07, 0.20)
P-int: 0.003
0.14 (0.06, 0.21)
0.05 (−0.01, 0.10)
P-int: 0.647
0.08 (0.01, 0.14)
0.11 (0.03, 0.20)
P-int: 0.162
0.07 (0.01, 0.13)
0.11 (0.04, 0.17)
P-int: 0.062
0.04 (−0.04, 0.13)
0.12 (0.06, 0.17)
P-int: 0.613
0.11 (−0.01, 0.23)
0.08 (0.02, 0.13)
P-int: 0.992
0.12 (−0.07, 0.32)
0.09 (0.04, 0.14)
P-int: 0.084
0.13 (0.03, 0.24)
− 0.01 (−0.12, 0.10)
P-int: 0.967
0.09 (0.03, 0.15)
0.09 (0.02, 0.15)
P-int: 0.352
0.12 (0.04, 0.20)
0.08 (0.02, 0.14)
P-int: 0.410
0.08 (−0.05, 0.21)
0.03 (−0.06, 0.12)
P-int: 0.172
0.03 (−0.06, 0.11)
0.09 (0.03, 0.15)
P-int: 0.860
0.09 (−0.03, 0.20)
0.06 (0.00, 0.13)
P-int: 0.993
0.09 (0.03, 0.14)
0.08 (0.00, 0.16)

Pooled MD
(95% CI)

Fine motor

17,741 (9)

18,414 (7)

12,154 (10)

11,513 (8)

19,992 (10)

22,544 (11)

3003 (4)

6662 (7)

6647 (7)

22,479 (11)

22,871 (11)

17,320 (8)

22,725 (11)

22,575 (11)

18,333 (9)

21,633 (10)

n (comp)

P-int: 0.787
0.09 (0.03, 0.15)
0.07 (0.04, 0.11)
P-int: 0.787
0.09 (0.03, 0.15)
0.07 (0.04, 0.11)
P-int: 0.610
0.06 (0.02, 0.10)
0.06 (0.02, 0.11)
P-int: 0.104
0.07 (0.02, 0.11)
0.06 (0.02, 0.09)
P-int: 0.753
0.06 (0.03, 0.10)
0.06 (0.00, 0.12)
P-int: 0.155
0.07 (0.03, 0.11)
0.05 (0.01, 0.09)
P-int: 0.145
0.01 (−0.04, 0.06)
0.08 (0.05, 0.12)
P-int: 0.312
0.12 (0.01, 0.22)
0.05 (0.00, 0.09)
P-int: 0.417
0.11 (−0.06, 0.29)
0.07 (0.02, 0.11)
P-int: 0.658
0.08 (−0.01, 0.17)
0.02 (−0.09, 0.13)
P-int: 0.091
0.09 (0.05, 0.13)
0.03 (0.00, 0.07)
P-int: 0.951
0.07 (0.01, 0.13)
0.06 (0.02, 0.09)
P-int: 0.883
0.07 (−0.01, 0.15)
0.08 (0.03, 0.14)
P-int: 0.943
0.05 (−0.01, 0.10)
0.08 (0.03, 0.12)
P-int: 0.300
0.02 (−0.03, 0.08)
0.06 (0.02, 0.09)
P-int: 0.958
0.07 (0.03, 0.11)
0.06 (0.01, 0.10)

Pooled MD
(95% CI)

Gross motor

1 comp, number of intervention against control group comparisons; Hb, hemoglobin; LAZ, length-for-age z score; MD, mean difference in fixed-effects models; n, number of individual participants; P-int, P value for the interaction indicating the difference in effects of
small-quantity lipid-based nutrient supplements between the 2 levels of the effect modifier in fixed-effects models; SES, socioeconomic status; SQ-LNS, small-quantity lipid-based nutrient supplement.

Maternal height, cm
<150.1
≥150.1
Maternal BMI, kg/m2
<20
≥20
Maternal age, y
<25
≥25
Maternal education
<Primary
≥Primary
Maternal depressive symptoms
<75th percentile
≥75th percentile
Child sex
Male
Female
Child birth order
Firstborn
Later-born
Child stunted
LAZ < −2
LAZ ≥ −2
Child acute malnutrition
Acutely malnourished
Not acutely malnourished
Child anemia
Hb <110 g/L
Hb ≥110 g/L
Household SES
<Study median
≥Study median
Household food insecurity
Moderate to severe
Mild to none
Household source water quality
Unimproved
Improved
Household sanitation
Unimproved
Improved
Home environment
<Study median
≥Study median
Season
Dry
Rainy

n (comp)

Language

TABLE 5 Individual-level effect modifiers of effects of SQ-LNSs provided to infants and young children age 6–24 mo on continuous developmental outcomes1
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Supplement

Maternal height, cm
<150.1
≥150.1
Maternal BMI, kg/m2
<20
≥20
Maternal age, y
<25
≥25
Maternal education
<Primary
≥Primary
Maternal depressive
symptoms
<75th percentile
≥75th percentile
Child sex
Male
Female
Child birth order
Firstborn
Later-born
Child stunted
LAZ < −2
LAZ ≥ −2
Child acute malnutrition
Acutely malnourished
Not acutely
malnourished
Child anemia
Hb <110 g/L
Hb ≥110 g/L

3110 (4)

4067 (3)

6776 (6)

22,225 (9)

24,262 (12)

17,310 (7)

19,704 (7)

23,678 (11)

18,852 (9)

15,675 (4)

n (comp)

P-int: 0.847
0.91 (0.66, 1.25)
0.88 (0.64, 1.21)

0.83 (0.73, 0.94)
0.95 (0.80, 1.14)
P-int: 0.255
0.89 (0.79, 1.00)
0.76 (0.67, 0.87)
P-int: 0.362
0.91 (0.77, 1.09)
0.80 (0.71, 0.90)
P-int: 0.111
0.62 (0.49, 0.79)
0.75 (0.63, 0.89)
P-int: 0.588
0.67 (0.46, 0.99)
0.65 (0.53, 0.80)

P-int: 0.678
0.87 (0.70, 1.08)
0.86 (0.74, 1.00)
P-int: 0.149
0.83 (0.71, 0.98)
0.76 (0.67, 0.87)
P-int: 0.832
0.83 (0.73, 0.94)
0.84 (0.74, 0.95)
P-int: 0.804
0.89 (0.77, 1.02)
0.86 (0.74, 0.99)
P-int: 0.204

Pooled PR
(95% CI)

Language lowest decile

3107 (4)

3476 (2)

5588 (4)

22,137 (9)

23,588 (11)

17,523 (8)

18,982 (6)

22,997 (10)

19,342 (9)

9707 (3)

n (comp)

P-int: 0.881
0.89 (0.67, 1.18)
0.89 (0.62, 1.26)

0.80 (0.70, 0.91)
0.92 (0.76, 1.11)
P-int: 0.757
0.84 (0.74, 0.95)
0.80 (0.70, 0.92)
P-int: 0.920
0.85 (0.71, 1.01)
0.82 (0.73, 0.92)
P-int: 0.728
0.67 (0.51, 0.89)
0.73 (0.59, 0.89)
P-int: —
—
—

P-int: 0.638
0.89 (0.73, 1.08)
0.86 (0.69, 1.06)
P-int: 0.199
0.88 (0.75, 1.03)
0.76 (0.66, 0.88)
P-int: 0.546
0.81 (0.71, 0.93)
0.86 (0.75, 0.98)
P-int: 0.638
0.87 (0.75, 1.01)
0.90 (0.77, 1.06)
P-int: 0.165

Pooled PR
(95% CI)

Social-emotional lowest decile

2662 (4)

—
—
—

2564 (3)

7427 (4)

8805 (6)

6494 (3)

6636 (4)

7984 (5)

7821 (5)

5144 (2)

n (comp)

P-int: 0.464
0.88 (0.61, 1.27)
1.07 (0.76, 1.52)

0.94 (0.78, 1.15)
0.81 (0.58, 1.13)
P-int: 0.231
0.83 (0.66, 1.04)
0.95 (0.80, 1.13)
P-int: 0.144
0.75 (0.56, 1.02)
0.97 (0.81, 1.15)
P-int: 0.507
1.14 (0.67, 1.93)
0.86 (0.64, 1.13)
P-int: —
—
—

P-int: —
—
—
P-int: 0.977
0.91 (0.73, 1.15)
0.86 (0.69, 1.07)
P-int: 0.088
0.79 (0.63, 1.00)
1.02 (0.84, 1.25)
P-int: 0.865
0.93 (0.72, 1.20)
0.90 (0.72, 1.12)
P-int: 0.394

Pooled PR
(95% CI)

Executive function lowest decile

2998 (4)

3906 (3)

6051 (5)

21,209 (8)

23,311 (11)

16,120 (6)

19,293 (7)

23,305 (11)

19,078 (9)

9576 (3)

n (comp)

P-int: 0.237
0.78 (0.57, 1.06)
1.07 (0.77, 1.49)

0.87 (0.76, 0.99)
0.82 (0.67, 1.01)
P-int: 0.701
0.83 (0.73, 0.95)
0.81 (0.71, 0.92)
P-int: 0.015
1.01 (0.84, 1.21)
0.76 (0.68, 0.86)
P-int: 0.870
0.73 (0.57, 0.93)
0.75 (0.62, 0.90)
P-int: 0.612
0.71 (0.48, 1.06)
0.72 (0.58, 0.88)

P-int: 0.550
0.87 (0.71, 1.07)
0.79 (0.63, 0.98)
P-int: 0.477
0.83 (0.71, 0.96)
0.79 (0.69, 0.90)
P-int: 0.466
0.88 (0.77, 1.00)
0.81 (0.71, 0.93)
P-int: 0.225
0.83 (0.72, 0.97)
0.95 (0.81, 1.11)
P-int: 0.649

Pooled PR
(95% CI)

Motor lowest decile

TABLE 6 Individual-level effect modifiers of effects of SQ-LNSs provided to infants and young children age 6–24 mo on binary developmental outcomes1

3013 (4)

8164 (4)

8941 (5)

13,587 (10)

13,841 (10)

7718 (5)

13,210 (7)

13,609 (9)

8942 (7)

6677 (5)

n (comp)

(Continued)

P-int: 0.526
1.12 (0.98, 1.27)
1.18 (1.05, 1.33)

1.14 (1.06, 1.23)
1.19 (1.04, 1.37)
P-int: 0.952
1.10 (1.03, 1.17)
1.09 (1.03, 1.15)
P-int: 0.025
1.05 (0.99, 1.11)
1.16 (1.09, 1.23)
P-int: 0.624
1.11 (0.98, 1.26)
1.09 (1.03, 1.15)
P-int: 0.133
1.19 (1.02, 1.38)
1.08 (1.03, 1.14)

P-int: 0.624
1.19 (1.02, 1.39)
1.20 (1.11, 1.29)
P-int: 0.343
1.11 (1.00, 1.24)
1.11 (1.03, 1.20)
P-int: 0.394
1.12 (1.05, 1.18)
1.07 (1.00, 1.14)
P-int: 0.792
1.09 (1.02, 1.16)
1.10 (1.04, 1.16)
P-int: 0.543

Pooled PR
(95% CI)

Walking without support at 12 mo
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18,846 (9)

19,878 (8)

4971 (3)

11,079 (6)

20,532 (9)

23,938 (12)

n (comp)

16,656 (6)

19,742 (8)

7706 (4)

11,081 (6)

0.78 (0.67, 0.91)
0.85 (0.76, 0.95)
P-int: 0.707
0.76 (0.62, 0.92)
0.80 (0.66, 0.96)
P-int: 0.821
0.85 (0.65, 1.10)
0.75 (0.60, 0.94)
P-int: 0.592
0.86 (0.75, 0.99)
0.89 (0.77, 1.03)
P-int: 0.524
0.82 (0.72, 0.94)
0.83 (0.72, 0.96)

19,715 (8)

23,263 (11)

n (comp)

0.76 (0.61, 0.94)
0.75 (0.61, 0.92)
P-int: 0.304
0.76 (0.61, 0.97)
0.88 (0.71, 1.09)
P-int: 0.863
0.85 (0.74, 0.98)
0.89 (0.77, 1.02)
P-int: 0.584
0.75 (0.64, 0.88)
0.84 (0.72, 0.98)

0.81 (0.69, 0.95)
0.81 (0.71, 0.92)
P-int: 0.534

P-int: 0.655
0.81 (0.72, 0.92)
0.83 (0.71, 0.95)
P-int: 0.325

Pooled PR
(95% CI)

Social-emotional lowest decile

P-int: 0.227
0.81 (0.72, 0.91)
0.88 (0.76, 1.00)
P-int: 0.772

Pooled PR
(95% CI)

Language lowest decile

6749 (3)

6636 (4)

1455 (2)

2294 (2)

8036 (5)

8064 (5)

n (comp)

—
—
P-int: —
—
—
P-int: 0.287
1.02 (0.82, 1.27)
0.84 (0.67, 1.05)
P-int: 0.819
0.87 (0.71, 1.07)
0.93 (0.72, 1.19)

0.91 (0.71, 1.17)
0.87 (0.73, 1.04)
P-int: —

P-int: 0.389
0.86 (0.70, 1.06)
0.96 (0.78, 1.18)
P-int: 0.640

Pooled PR
(95% CI)

Executive function lowest decile

17,934 (8)

19,514 (8)

7500 (4)

11,034 (6)

19,484 (8)

22,985 (11)

n (comp)

0.72 (0.59, 0.88)
0.82 (0.68, 0.99)
P-int: 0.228
0.98 (0.79, 1.22)
0.80 (0.63, 1.00)
P-int: 0.766
0.86 (0.75, 0.99)
0.85 (0.72, 0.99)
P-int: 0.839
0.80 (0.71, 0.91)
0.85 (0.73, 1.00)

0.78 (0.65, 0.93)
0.85 (0.75, 0.95)
P-int: 0.723

P-int: 0.878
0.83 (0.74, 0.93)
0.83 (0.72, 0.95)
P-int: 0.594

Pooled PR
(95% CI)

Motor lowest decile

9043 (7)

8353 (6)

8584 (5)

3205 (5)

13,076 (7)

13,519 (9)

n (comp)

1.17 (0.95, 1.43)
1.09 (0.98, 1.21)
P-int: 0.336
1.07 (0.99, 1.16)
1.07 (1.00, 1.15)
P-int: 0.458
1.11 (1.00, 1.23)
1.15 (1.07, 1.24)
P-int: 0.845
1.17 (1.08, 1.27)
1.11 (1.02, 1.20)

1.10 (1.02, 1.18)
1.09 (1.03, 1.14)
P-int: 0.190

P-int: 0.721
1.09 (1.02, 1.16)
1.08 (1.03, 1.14)
P-int: 0.812

Pooled PR
(95% CI)

Walking without support at 12 mo

1 comp, number of intervention against control group comparisons; Hb, hemoglobin; LAZ, length-for-age z score; n, number of individual participants; P-int, P value for the interaction indicating the
difference in effects of small-quantity lipid-based nutrient supplements between the 2 levels of the effect modifier in fixed-effects models; PR, prevalence ratio in fixed-effects models; SES, socioeconomic
status; SQ-LNS, small-quantity lipid-based nutrient supplement.

Household SES
<Study median
≥Study median
Household food
insecurity
Moderate to severe
Mild to none
Household source water
quality
Unimproved
Improved
Household sanitation
Unimproved
Improved
Home environment
<Study median
≥Study median
Season
Dry
Rainy

TABLE 6 (Continued)
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FIGURE 7 Pooled effects of SQ-LNSs on 6 primary developmental outcomes stratified by individual-level household SES. Individual study estimates
for interaction effect were generated from log-binomial regression controlling for baseline measure when available and with clustered observations using
robust SEs for cluster-randomized trials. Pooled subgroup estimates and statistical testing of the pooled interaction term were generated using inverse-variance
weighting fixed effects. ∗∗P-Int < 0.01, ∗P-Int < 0.1 P-int, P value for the interaction indicating the difference in effects of small-quantity lipid-based nutrient
supplements between the 2 levels of the effect modifier in fixed-effects models. LNS, lipid-based nutrient supplement; SES, socioeconomic status.

of children’s foods with multiple micronutrient powders was
not able to calculate pooled effects on developmental outcomes
(50). Therefore, it is difficult to compare the effects of SQLNSs with the effects of other types of nutritional supplements.
However, in Prado et al. (49), pooled effect sizes for language,
social-emotional, and motor scores were similar in trials that
provided multiple micronutrients with macronutrients (0.09–
0.10 SD; 10–17 trials) and in trials that provided multiple
micronutrients without macronutrients (0.08–0.11 SD; 5–11
trials). This suggests that the multiple micronutrients in SQ-LNSs
may be key ingredients for effects on developmental outcomes.
However, further research is needed to understand how SQ-LNS
compares with other types of nutritional supplements designed
to fill nutrient gaps in children’s diets, such as micronutrient
powders and fortified blended foods, with regard to effects
on child development. One difference between SQ-LNSs and
other products that contain both macro- and micronutrients is
that SQ-LNSs contain substantial amounts of essential fatty

acids, important for brain development, whereas other energycontaining supplements may not.
Our study is the first meta-analysis that we know of to report
effects of child nutritional supplementation on reducing the
prevalence of children in the lowest decile of developmental
scores. We used the lowest decile of scores as a proxy for
children who may be at the greatest risk of developmental delay.
Typically, distributions of developmental assessment scores in
LMIC settings have a left tail that is larger than the right
tail, comprised of children who score substantially lower than
their age- and sex-matched peers and may be developmentally
delayed. In most of the studies in this IPD meta-analysis (in
9 of 13 comparisons for language, 10 of 12 for motor, and
8 of 11 for social-emotional scores), a greater proportion of
children scored <2 SD below the mean (overall ∼3%) than
>2 SD above the mean (<1%). The finding of significant
reductions in the lowest decile of scores shows that SQ-LNS
not only shifts the mean of the distribution, but also improves
outcomes among children in the lower tail of the distribution

FIGURE 8 Pooled effects of SQ-LNSs on 6 primary developmental outcomes stratified by individual-level child baseline acute malnutrition. Individual
study estimates for interaction effect were generated from log-binomial regression controlling for baseline measure when available and with clustered
observations using robust SEs for cluster-randomized trials. Pooled subgroup estimates and statistical testing of the pooled interaction term were generated
using inverse-variance weighting fixed effects. ∗∗P-Int < 0.05 P-int, P value for the interaction indicating the difference in effects of small-quantity lipid-based
nutrient supplements between the 2 levels of the effect modifier in fixed-effects models. LNS, lipid-based nutrient supplement.
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FIGURE 9 Pooled effects of SQ-LNSs on 6 primary developmental outcomes stratified by individual-level child baseline stunting. Individual study
estimates for interaction effect were generated from log-binomial regression controlling for baseline measure when available and with clustered observations
using robust SEs for cluster-randomized trials. Pooled subgroup estimates and statistical testing of the pooled interaction term were generated using inversevariance weighting fixed effects. LNS, lipid-based nutrient supplement.

who may be at particular risk of developmental delay. Attaining
developmental skills that are appropriate for the child’s age
is likely to facilitate further advances in development because
many skills developed at later stages build on those that were
learned previously. For example, acquiring the skill of walking
without support is a catalyst for change in multiple domains
of development (51). Both the reduction in the percentage of
children in the lowest decile of scores and the increase in
the percentage of children walking without support with SQLNSs could be important for supporting healthier developmental
trajectories in the population. The percentage of children walking
without support in the SQ-LNS groups (45% overall compared
with 39% in control groups) is closer to the prevalence in the
WHO Multi-Center Growth Reference study, which showed that
in a healthy group of children, 50% were walking without support
at age 12 mo (52). Further research is needed to understand
the longer-term effects of SQ-LNSs on developmental outcomes
and whether the observed positive effects at 12–24 mo are
sustained into later childhood. Two of the trials in this IPD
meta-analysis conducted follow-up assessments at age 3–6 y.
One follow-up study in Bangladesh found significantly higher
composite cognitive scores (+0.13 SD) in the SQ-LNS group
(53), whereas the other follow-up study in Ghana showed reduced
social-emotional difficulties (−0.12 SD) in the SQ-LNS group,
with greater effects among children with lower-quality home
environments (−0.22 SD) (54).
Among the 6 trials (7 comparisons) that assessed executive
function, no overall effects of SQ-LNSs were found. Executive
function is the cognitive control of attention, self-regulation, and
emotion, including the ability to plan and monitor actions, selfregulate actions and emotions, focus and sustain attention, and
maintain information in short-term memory (55). These skills and
the neural structures that underlie them (the prefrontal cortex and
other connected cortical and subcortical structures) experience
their peak rate of development in later childhood and adolescence
(56). Therefore, 6–24 mo of age may be too early for nutritional
supplementation to have a measurable effect on the development
of executive function. It is also possible that the A not B task
might not be the most robust assessment of executive function
at this age. Future studies should consider other measures of

executive function. Future studies should also consider the age
of child assessments when deciding whether to monitor the
acquisition of the WHO motor milestones, given that across these
13 studies, variance was found at 12 mo, but ceiling effects were
present at age 18 mo.
Comparing the all-trials analysis with the child-LNS-only
analysis, we did not find evidence that maternal LNS provided an
added benefit for developmental outcomes compared with child
SQ-LNS only; however, only 4 trials included maternal LNS arms
(29, 37, 40, 43). This absence of an additive effect is consistent
with the 2 trials that directly compared arms providing maternal
plus child LNS with child SQ-LNS only, which did not find
differences between these arms in developmental outcomes (29,
37). This is also consistent with previous meta-analyses, which
have found positive effects of child but not maternal nutritional
supplementation on developmental outcomes (47, 48). In our
“separation of multicomponent arms” sensitivity analysis, which
limited comparisons to pairs of arms with the same nonnutrition
components, and also excluded the maternal LNS trials/arms,
results were nearly identical to those of the all-trials analysis. The
consistency across sensitivity analyses indicates that the all-trials
analysis, which includes a larger sample size and broader group
of trials, presents a valid estimate of the causal effect of child
SQ-LNSs.
Study-level effect modification
The child stunting burden in the study sample was the most
consistent effect modifier across developmental outcomes (5 of
the 8 developmental outcomes with sufficient data to analyze
this effect modifier). Stunted growth has been consistently
associated with poor developmental outcomes (57), therefore
stunted children may have greater potential to benefit from SQLNSs. Within the control groups in this IPD meta-analysis,
stunted children scored significantly lower than nonstunted
children in language and motor scores in all trials, and in socialemotional scores in all trials except 1. Recent evidence suggests
that stunted growth does not cause delayed neurodevelopment,
but instead is a sensitive marker of an environment that constrains
growth and development through partly overlapping causes (49,
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58). High child anemia prevalence, which also modified effects
of SQ-LNSs on motor outcomes, may also be a marker of a
high-risk environment in which children have greater potential
to benefit from SQ-LNSs. The findings from this IPD metaanalysis show that inadequate dietary intake is one of the shared
causes of faltering in both linear growth and development, as
well as anemia, and that SQ-LNS has positive effects on all of
these outcomes (12, 59). However, patterns of effect modification
were different; greater effects on linear growth were not found
in studies with a higher stunting burden. Linear growth may be
less malleable to recovery through intervention after early growth
restriction (e.g., in utero and from birth to 6 mo of age), whereas
development may be more responsive to postnatal intervention
because brain plasticity continues throughout childhood (1).
Apart from stunting and anemia prevalence, we did not find
significant effect modification by other study-level characteristics. In all study-level subgroups, effect sizes were consistently
in the expected direction favoring SQ-LNS groups. This suggests
that effects are evident across a range of contexts from low to
high malaria prevalence, water quality, supplementation duration,
frequency of contact, and average compliance with SQ-LNSs.
However, in the study-level meta-regression analyses, we had
limited power to detect significant associations between studylevel effect modifiers and effect sizes owing to small sample
sizes (a maximum of n = 13 intervention against control
group comparisons). For example, the relative reduction in
the prevalence of children in the lowest decile of language
scores was 22% among studies with higher malaria prevalence
compared with 7% among studies with lower malaria prevalence.
With additional studies and thus power, it is possible that such
differences could reach significance. One exception was that the
effect of SQ-LNSs on executive function significantly differed
between studies with a low and studies with a high prevalence of
improved sanitation. However, given the lack of overall effect of
SQ-LNSs on executive function and given that CIs around the
executive function estimates in both subgroups (high and low
prevalence of improved sanitation) included 0, it is likely that
there was no true effect on executive function in either subgroup.
Individual-level effect modification
Just as the study-level effect modification analysis showed
that populations in higher-risk environments, as indicated by
higher prevalence of child stunting and anemia, had greater
potential to benefit from SQ-LNSs in developmental outcomes,
the individual-level effect modification analysis consistently
showed that certain subgroups of children who may be in higherrisk circumstances had a greater potential to benefit from SQLNSs, including children who were stunted, anemic, acutely
malnourished, in low-SES households, later-born, and whose
mothers were older and less educated. As previously discussed
for stunted children, in our pooled control group data, children
in all of these categories, except children of older mothers, had
lower language and motor scores and therefore had greater room
for improvement in developmental skills. Iron deficiency anemia,
acute malnutrition, low SES, and low maternal education are
associated with poor development (60, 61). Later-born children
may have access to fewer household and caregiving resources
because they are competing with older siblings, which may
negatively affect their development. Although it is not clear why
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children of older mothers might be at higher risk, older mothers
tended to be less educated and their children tended to be laterborn, thus these subgroups overlapped (46% of older mothers
completed primary school, whereas 59% of younger mothers
completed primary school; 84% of older mothers’ children were
later born, whereas 46% of younger mothers’ children were later
born; 75% of lower educated mothers’ children were later born,
whereas 56% of higher educated mothers’ children were later
born).
Although the findings generally show that children in higherrisk environments have greater potential to benefit in developmental outcomes from SQ-LNSs, it is somewhat surprising
that indicators of maternal depressive symptoms and the home
environment did not modify effects of SQ-LNSs in this IPD metaanalysis. Similarly to stunted and malnourished children, children
of mothers with depressive symptoms and children in lowquality home environments also tend to have poor developmental
scores (62, 63). Three SQ-LNS trials have found that children in
lower-quality home environments show greater benefits of SQLNSs on developmental outcomes (38, 40, 54). One of these
was a follow-up study at age 4–6 y that was not included in
this IPD meta-analysis. However, findings from this IPD metaanalysis suggest that effects of SQ-LNSs on development are
generalizable regardless of maternal depressive symptoms and
home environment, at least across the range represented in
these studies. Similarly, lack of effect modification based on
child sex, household food insecurity, water quality, sanitation,
maternal BMI, and season suggests that effects on developmental
outcomes are generalizable across these characteristics.
Strengths and limitations of this IPD meta-analysis
This IPD meta-analysis had many strengths. A substantial
number of high-quality trials that provided similar types of
SQ-LNS products to children age 6–24 mo were included.
Investigators from all but 1 of the eligible studies participated
and the sample size was very large. The availability of IPD
allowed harmonization of calculation of developmental outcomes
across trials, and enabled incorporation of cluster-randomized
trials using robust SEs and allowing for study-specific intracluster
correlations. The 13 study sites were highly diverse in terms
of sample characteristics and study designs, which provided
heterogeneity for exploration of study-level effect modifiers.
The consistency of findings across fixed- and random-effects
models and sensitivity analyses strengthens confidence in the
conclusions.
This IPD meta-analysis also had limitations. We were unable
to calculate pooled estimates for effects on general nonverbal
cognitive skills because only 2 trials measured this domain (21,
29). Although we were able to harmonize the calculation of
developmental assessment scores across trials, different tools
were used in different trials and we did not have an external
reference to standardize scores. Thus, although all developmental
scores were calculated in units of SD based on the within-study
distribution, if SDs varied across studies, the point value of
1 SD could be larger in one trial than another, and interpretation
of effect sizes would be different across trials. For example,
among the 6 studies that used a 10-item A not B task to assess
executive function, SDs ranged from 1.4 to 2.5; and among
the 5 studies that used a 100-word vocabulary checklist to
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assess language, SDs ranged from 18.9 to 23.5. Ongoing efforts
to develop a standardized scale of developmental scores will
greatly improve future meta-analyses of developmental outcomes
(64). Future research should also use developmental assessments
directly observed by blinded assessors, at least in a subset of
children, to address the potential risk of bias when parent-report
developmental assessment tools are used in trials in which the
intervention precludes participant blinding.
Another limitation was the limited diversity of geographical
region. The majority of studies were conducted in Sub-Saharan
Africa, with only 1 country representing the WHO Southeast
Asia Region (Bangladesh) and 1 country representing Latin
America and the Caribbean (Haiti). In addition, not all trials
were included in all analyses because some trials did not
measure some outcomes (e.g., executive function) or effect
modifiers (e.g., baseline child stunting, maternal depressive
symptoms, home environment). For study-level effect modifiers,
statistical power was constrained by the limited number of
trials. For individual-level effect modifiers, although we made
every effort to standardize definitions and cutoffs for potential
effect modifiers, there was variation across trials in the methods
used to collect information on certain characteristics, such
as household food insecurity and socioeconomic status. We
examined multiple effect modifiers and numerous outcomes, so
several of the significant P-for-interaction values are likely due
to chance. As stated in the Methods, we did not adjust for
multiple hypothesis testing because developmental outcomes are
interrelated and the effect modification analyses are inherently
exploratory. Lastly, caution is needed when interpreting the
effect modification results because many of the potential effect
modifiers are interrelated and also may be confounded by
unmeasured variables. Thus, attribution of the relative potential to
benefit from or respond to SQ-LNSs to a particular characteristic
may not be warranted.
Programmatic implications
Our findings suggest that if policy-makers and program planners implement SQ-LNS distribution to children age 6–24 mo,
they can expect modest, but potentially important, developmental
gains among children in the population, particularly in areas with
high child stunting burden. If the goal of a policy or program is
to target not only developmental outcomes, but also child growth,
iron deficiency, anemia, and mortality, then SQ-LNSs should
be considered. To our knowledge, SQ-LNS is the only child
nutrition intervention that has been documented in meta-analyses
to have positive effects on all of these outcomes (12, 59, 65). As
aforementioned, few previous meta-analyses of specific types of
nutritional supplements have been able to calculate pooled effects
on developmental outcomes.
However, if the primary goal of a policy or program is
to improve developmental outcomes, investment is needed not
only in nutrition but also in other aspects of nurturing care,
especially responsive care and learning opportunities (66).
For all developmental domains, interventions that promote
responsive care and learning opportunities have effect sizes
4–5 times larger (analogous to ∼5–7 IQ points) than those
for nutritional supplementation alone (49). Integration of SQLNSs with such programs should be considered. One advantage
of integrating nutrition with caregiving interventions could be

incentivizing participation in parenting groups or home visits
through provision of SQ-LNSs, thereby increasing coverage (67).
Another advantage of integration is building on existing contact
points between community front-line workers and families with
young children, thus potentially reducing implementation costs
(68). The cost of SQ-LNSs is estimated at $0.07–0.14 per child
per day not including distribution costs (which may be the bulk
of program costs), depending on scale and location of production
(69, 70). Further research is needed on the costs of programs
promoting responsive care and learning opportunities targeting
young children in LMICs and integration of such programs with
nutrition programs (71).
We consistently found that certain groups of children in higherrisk environments showed greater benefits in developmental
outcomes from SQ-LNSs, such as children from low-SES
households. This suggests that implementing SQ-LNS programs
will promote equity, which is at the core of achieving the
Sustainable Development Goals and ensuring that no child is left
behind. However, we also found that children from the lower-risk
groups (e.g., those from higher-SES households) showed positive
effects. Similarly, although the reduction in the prevalence of
children in the lowest decile showed gains from SQ-LNSs for the
most marginalized children, the significant shifts in mean scores
showed that children across the full distribution benefited from
SQ-LNSs. We recommend that decisions regarding targeting
specific communities or households be based on the wider body
of evidence on all outcomes, including nutritional status and
growth, not only developmental outcomes.
Our findings also have implications for programs designed
for community management of acute malnutrition (CMAM).
Many CMAM programs provide large-quantity LNSs (∼1000–
1500 kcal/d) to children who meet the cutoffs for severe
acute malnutrition (WLZ < −3 SD or MUAC <115 mm),
according to WHO guidelines (72). Medium-quantity LNSs
(∼250–500 kcal/d) are typically used to treat moderate acute
malnutrition (MAM; −3 < WLZ < −2 SD or 115 < MUAC
< 125 mm); however, the coverage of MAM treatment is low.
Most evidence for the efficacy of MAM treatment has focused on
child survival and recovery, rather than developmental outcomes
(73). We found that provision of SQ-LNSs to children who
experienced MAM at baseline increased developmental scores
by 0.3 SD, which is the largest effect size observed in any
subgroup, analogous to ∼5 IQ points, and >3 times larger than
the overall effect of SQ-LNSs. This suggests that these children
have high potential to benefit from LNS distribution programs in
developmental outcomes, and that investment in such programs
will advance not only child survival, but also fulfillment of
developmental potential among the most vulnerable.

Conclusions
SQ-LNSs can fill nutrient gaps in children’s diets in key
nutrients that are necessary for brain development. Given that
provision of SQ-LNSs has been documented in meta-analyses to
positively affect not only nutritional status and growth, but also
child survival and development, it is one of the few interventions
that is known to be effective to address multiple pillars of the
UN’s Global Strategy for Women’s, Children’s and Adolescents’
Health (2016–2030), which targets 3 pillars of survival (ending
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preventable deaths), thriving (ensuring health and well-being),
and transformation (expanding enabling environments).
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